



(19) Eur pâisches Patentamt  
 European Patent Office  
 Office européen des brevets



(11) Publication number:

**0 213 272 B1**

(12)

## EUROPEAN PATENT SPECIFICATION

- (45) Date of publication of patent specification: **09.09.92** (51) Int. Cl. 5: **A61K 31/40, A61K 37/02, A61K 41/00, //C07D487/22, (C07D487/22,257:00,209:00, 209:00,209:00,209:00)**  
 (21) Application number: **86105955.8**  
 (22) Date of filing: **30.04.86**

(54) New tetrapyrrole polyaminomonocarboxylic acid therapeutic agents.

(33) Priority: **30.04.85 US 728752**

(43) Date of publication of application:  
**11.03.87 Bulletin 87/11**

(45) Publication of the grant of the patent:  
**09.09.92 Bulletin 92/37**

(84) Designated Contracting States:  
**AT BE CH DE FR GB IT LI LU NL SE**

(56) References cited:

EP-A- 0 142 732	EP-A- 0 168 831
EP-A- 0 168 832	WO-A-84/01382
DE-A- 2 809 093	US-A- 4 393 071

(73) Proprietor: **Nippon Petrochemicals Co., Ltd.  
 Salwal Building, 1-3-1 Uchisalwal-cho  
 Chiyoda-ku  
 Tokyo(JP)**

(72) Inventor: **Bommer, Jerry C.  
 Rural Route No. 2 Box 516  
 Ogden Utah(US)  
 Inventor: Burnham, Bruce F.  
 127 West 900 North  
 Logan Utah(US)**

(74) Representative: **Lehn, Werner, Dipl.-Ing. et al  
 Hoffmann, Eltje & Partner Patentanwälte Ar-  
 abellastrasse 4  
 W-8000 München 81(DE)**

**EP 0 213 272 B1**

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).

**Description**

This invention relates to new therapeutic compositions which are useful in photodiagnosis and phototherapy, especially in the detection and treatment of tumors and cancerous tissues in the human or animal body.


It is known to irradiate tumors and cancerous tissues in the human body with intensive light following administration of a hematoporphyrin derivative in the wavelength range of 626 to 636 nanometers to reduce and, at times, destroy the cancerous cells (see PCT published specification WO 83/00811). It is also known that porphyrins, especially the sodium salt of protoporphyrins, can maintain or promote the normal functions of cells and are useful for preventing the genesis, growth, metastasis, and relapse of malignant tumors. Japanese Published Patent Application No. 125737/76 describes the use of porphyrins as tumor inhibiting agents, exemplifying etioporphyrin, mesoporphyrin, protoporphyrin, deuteroporphyrin, hematoporphyrin, coproporphyrin, and uroporphyrin.

In Tetrahedron Letters No. 23, pp. 2017 - 2020 (1978) describes an amino monocarboxylic acid adduct of the pigment bonellin obtained by extraction of principally the body wall of the marine echinoid B. viridis. The structure of these adducts is presumed to be an amide formed through either of the free carboxy groups of bonellin and the amino mono-carboxylic acid. Hydrolysis of the adduct yielded a mixture of valine, isoleucine, leucine and alloisoleucine. No use for these amino acid adducts is described in this reference.

That the tetrapyrroles cause intense photosensitivity in animals is well known and has been documented in numerous articles in literature, e.g., J. Intr. Sci. Vitaminol, 27, 521-527 (1981); Agric. Biol. Chem., 46(9), 2183-2193 (1982); Chem. Abst. 98, 276 (1983) and 88 6976m (1928).

EP-A-0142732 describes pheophorbide derivatives and alkali metal salts thereof as useful compounds in cancer treatment.

The therapeutic agents contemplated by this invention are cyclic tetrapyrroles derived by various procedures from naturally-occurring tetrapyrroles. The cyclic tetrapyrroles have as their common parent tetrapyrrole, uroporphyrinogen, and possess the following ring structure:



in which the positions in the molecule are numbered 1-20, and the rings identified by letters A, B, C and D, and also include perhydro-, e.g., dihydro- and tetrahydro-, derivatives of the said ring structure, e.g., compounds in which one or more double bonds are absent. There are present in the ring system four pyrrole rings joined through the alpha positions of the respective pyrrole rings by a methine group, i.e., -CH=. The compounds of the present invention are designated as derivatives of the tetrapyrroles for convenience in the disclosure and the appended claims and it will be understood that the term "tetrapyrrole" will designate compounds of the characteristic ring structure designated hereinbefore as well as the corresponding perhydro derivatives.

The tetrapyrroles employed in the present invention are all derived by various means and various alteration procedures from natural tetrapyrroles. The naturally occurring tetrapyrroles have as their common ancestor uroporphyrinogen III, a hexahydroporphyrin reduced at the bridge positions. For example, synthetic or biosynthetic derivatives or products of protoporphyrins IX or protoporphyrinogen IX are well-known

in the art (see, for example, Porphyrins and Metalloporphyrins, K. Smith Elsivier; The Porphyrins (Vols. 1-7) D. Dolphin, Academic Press; and Biosynthetic Pathways, Vol. III, Chapter by B. Burnham, editor D.M. Greenberg, Academic Press).

5 The non-cyclic tetrapyrroles are commonly known as bile pigments and include, for example, bilirubin and biliverdin. These tetrapyrroles are also derived from protoporphyrin, e.g., as metabolic products in animals.

A further characteristic of the present new therapeutic composition is the presence of at least one amide linkage in a substituent at any of the numbered positions of the ring structure. These are present in the instant new compounds together with other substituents as defined hereinafter.

10 Subject matter of the present invention is therefore a therapeutic composition according to claim 1.

Preferred embodiments of this composition are subject matter of claims 2 to 5.

Further subject matter is the use according to claim 6.

15 Thus, the present invention contemplates the therapeutic compositions containing amino acid or peptide derivatives of compounds which contain the chromophore of porphyrins, chlorins or bacteriochlorins, as well as related porphyrin compounds. The peptide linkage involves a carboxy group of the chromophore-bearing compound and the amino group of the specified amino acid. The present new therapeutic compositions embrace, *inter alia*, derivatives of the tetrapyrroles which contain a free carboxy group. These derivatives include the major classes of tetrapyrroles: carboxy-containing porphyrins, chlorins, and bacteriochlorins, which are well-known to those skilled in this art.

20 The amino acid employed in the present invention to form the aforesaid peptide linkage are aminomonocarboxylic acids in which the amino group, of course, is located on a carbon atom of the monocarboxylic acid. The specific position of the amino group in the carbon atom chain is not critical, the only requirement that the amino group be available to form the requisite peptide linkage with the carboxyl group of the selected porphyrin. Thus, a variety of amino monocarboxylic acids are useful in the present invention, including serine, glycine,  $\alpha$ -aminoalanine,  $\beta$ -aminoalanine,  $\epsilon$ -amino-n-caproic acid, piperidine-2-carboxylic acid, piperidine-6-carboxylic acid, pyrrole-2-carboxylic acid, pyrrole-5-carboxylic acid, piperidine-6-propionic acid or pyrrole-5-acetic acid. These amino acids may be substituted with angular alkyl groups, such as methyl and ethyl groups, as well as other groups which do not adversely affect the capability of the amino group to form the peptide linkage, e.g., alkoxy groups, or acyloxy groups, and may also include 25 additional amino groups. The preferred amino acids are the naturally occurring  $\alpha$ -amino acids, serine, alanine, and glycine, which are readily available and up to the present, have provided the best results.

30 Exemplary compounds of the tetrapyrrole classes are illustrated in Table I in which the numbered positions of the tetrapyrrole ring structure are used to designate the position of the indicated substituent. The absence of double bonds in the ring system is designated under "dihydro" with each set of numbers (ring position) indicating the absence of a double bond between the designated positions.

40

45

50

55

TABLE I

	Ring Position								Dihydro			
	B	C	D	1	2	6	7	11	12	14	16	17
PORPHYRIN												
Coproporphyrin III	Me	Pr	Me	Pr	Me	Pr	Me	Pr	H	Pr	Me	---
Deuteroporphyrin IX	Me	H	Me	H	Me	H	Me	Pr	H	Pr	Me	---
Hematoporphyrin IX	Me	Me	Me	Me	Me	Me	Me	Pr	H	Pr	Me	---
	-CH <sub>2</sub>						-CH <sub>2</sub>					
								OH				
Protoporphyrin IX	Me	V	Me	V	Me	V	Me	Pr	H	Pr	Me	---
Photoprotoporphyrin IX (one of two isomers shown)	Me	V	{ -Me	=CHCHO	{ -Me		Pr	H	Pr	Me	6,7	
			-OH									
Mesoporphyrin IX	Me	Et	Me	Et	Me	Et	Me	Pr	H	Pr	Me	---
	{ H	{ H										
	{ Me	{ Et										
Transmesochlorin IX	Me	Et	{ H	{ H				Pr	H	Pr	Me	1,2
Transmesochlorin IX	Me	Et	{ H	{ H				Pr	H	Pr	Me	6,7
	{ Me	{ Et										

TABLE I - Cont'd.  
Ring Position

PORPHYRIN	A		B		C		D		Dihydr
	1	2	6	7	11	12	14	16	
<u>Chlorin e<sub>4</sub></u>	Me	V	Me	Et	Me	CO <sub>2</sub> H	Me	{ H Pr}	16,17
<u>Chlorin e<sub>8</sub></u>	Me	V	Me	Et	Me	CO <sub>2</sub> H	Ac	{ H Pr}	16,17
<u>Mesochlorin e<sub>4</sub></u>	Me	Et	Me	Et	Me	CO <sub>2</sub> H	Me	{ H Pr}	16,17
<u>Isochlorin e<sub>4</sub></u>	Me	V	Me	Et	Me	H	Ac	{ H Pr}	16,17
<u>Mesoisochlorin e<sub>4</sub></u>	Me	Et	Me	Et	Me	H	Ac	{ H Pr}	16,17
<u>Mesochlorin e<sub>6</sub></u>	Me	Et	Me	Et	Me	CO <sub>2</sub> H	Ac	{ H Pr}	16,17
<u>Bacteriochlorin e<sub>6</sub></u>	Me	ACl	{ H Me}	{ H Et}	Me	CO <sub>2</sub> H	Ac	{ H Pr}	6,7 16,17


PORPHYRIN	Ring Position																	
	A			B			C			D								
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	Dihydro
Bacteriochlorin e <sub>1</sub>	Me	AcL	{ H	{ H	Me	{ H	CO <sub>2</sub> H	Me	{ H	H	{ H	{ H	{ H	6,7				
			{ Me	{ Et					{ Pr		{ Pr	{ Me	{ Me	16,17				
Bacterioisochlorin e <sub>1</sub>	Me	AcL	{ H	{ H	Me	{ H	H	Ac	{ H	H	{ H	{ H	{ H	6,7				
			{ Me	{ Et					{ Pr		{ Pr	{ Me	{ Me	16,17				

Notes:

- Me: -CH<sub>3</sub> (Methyl group)  
 Pr: -CH<sub>2</sub>CH<sub>2</sub>COOH (Propionic acid group)  
 V: -CH=CH<sub>2</sub> (Vinyl group)  
 Et: -CH<sub>2</sub>CH<sub>3</sub> (Ethyl group)  
 Ac: -CH<sub>2</sub>COOH (Acetic acid group)  
 AcL: -CH<sub>3</sub>-CO- (Acetyl group)

The preferred tetrapyrrole carboxylic acids are those wherein at least three carboxylic acid groups are present in the tetrapyrrole, preferably asymmetrically attached to the porphyrin ring system, e.g., the carboxylic acid groups are present on the rings A and B side of the molecule or on the rings D and C side of the molecule.

The particularly preferred therapeutic compositions comprise a fluorescent mono, di, or polyamide of an aminomonocarboxylic acid and a tetrapyrrol of the formula:



wherein;

X = H, vinyl, ethyl, acetyl or formyl;

Y = methyl or formyl;

25 M = methyl; and

E = ethyl

and pharmaceutically-acceptable salts thereof.

The compounds of the therapeutic composition form salts with either acids or bases. The acid salts are particularly useful for purification and/or separation of the final amide products as are the salts formed with bases. The base salts, however, are particularly preferred for diagnostic and therapeutic use as her in-described.

The acid salts are formed with a variety of acids such as the mineral acids, hydrochloric, hydrobromic, nitric and sulfuric acids, organic acids such as toluenesulfonic and benzenesulfonic acids.

The base salts include, for example, sodium, potassium, calcium, magnesium, ammonium, triethylammonium, trimethylammonium, morpholine or piperidine salts.

The acid and base salts are formed by the simple expediency of dissolving the selected amino acid tetrapyrrole amide in an aqueous solution of the acid or base and evaporation of the solution to dryness. The use of a water-miscible solvent for the amide can assist in dissolving the amide.

The final amide products can also be converted to metal complexes for example by reaction with metal salts. The magnesium complexes may be useful for the same purpose as the adduct product. Other metal complexes, as well as the magnesium complex, including, for example, iron and zinc, are useful to preclud contamination during processing of the adduct product by metals such as nickel, cobalt and copper, which are difficult to remove. Zinc and magnesium are readily removed from the final adduct product after processing is completed.

45 Since many of the aminomonocarboxylic acids exist in both the D- and L-forms, and also are employ d in mixtures of these forms as well as the D,L-form, the selection of the starting amino acid will, of course, result in products in which the respective isomer or mixture of isomers exist. The present invention contemplates the use of all such isomers, but the L-form is particularly preferred.

The present new compounds are prepared by the usual peptide synthetic routes which generally include any amide-forming reaction between the selected amino acid and the specific tetrapyrrole. Thus, any amide-forming derivative of the tetrapyrrole carboxylic acid can be employed in producing the present new peptides, e.g., lower alkyl esters, anhydrides and mixed anhydrides.

55 The preferred preparativ methods use mixed anhydrides of the carboxylic acid or carbodiimides. The reactants are merely contacted in a suitable solvent therefor and allowed to react. Temperatur s up to the reflux temperature can be used, with the higher t mperatures merely reducing the reaction time. Howev r, excessively high temperatures are usually not preferr d so as to avoid unwanted secondary reactions.

The procedures for forming th instant peptides ar well known in this art and are provided in detail in th accompanying examples.

Since the selected tetrapyrrole contains more than one carboxyl group, mixtures of products can be formed including isomeric di- and even tri- or higher peptid products, depending on the number of carboxyl groups and depending on the selected stoichiometry. Thus, when equivalent mixtures of amino acid and tetrapyrrol are reacted, the product may contain some monopeptides, but also present will be di- or polypeptides. It is generally possible to separate the monopeptides and higher peptides using known chromatographic techniques. However, such separations are not necessary since the mixed peptides are usually comparable to the separated products in their ultimate use. Thus, mixtures of mono, di, and tri-peptides of the same tetrapyrrole can be used.

Usually, unreacted tetrapyrrole is separated from the peptide products of the invention during purification as, for example, by chromatographic techniques.

#### Photodiagnosis and Phototherapy

The compositions of the present invention are useful for the photodiagnosis and phototherapy of tumor, cancer and malignant tissue (hereinafter referred to as "tumor").

When a man or animal having tumor is treated with doses of a compound of the present invention and when appropriate light rays or electromagnetic waves are applied, the compound emits light, i.e., fluorescence. Thereby the existence, position and size of tumor can be detected, i.e., photo-diagnosis.

When the tumor is irradiated with light of proper wavelength and intensity, the compound is activated to exert a cell killing effect against the tumor. This is called "phototherapy".

Compounds intended for photodiagnosis and phototherapy ideally should have the following properties:

- (a) non-toxic at normal therapeutic dosage unless and until activated by light;
- (b) should be selectively photoactive;
- (c) when light rays or electromagnetic waves are applied, they should emit characteristic and detectable fluorescence;
- (d) when irradiated with light rays or electromagnetic waves are applied, they are activated to an extent to exert a cell killing effect against tumor; and
- (e) easily metabolized or excreted after treatment.

In accordance with testing up to the present, the present new compounds have the foregoing properties and are also characterized by reasonable solubility in saline at physiological pH.

The compounds in the present composition possess greater fluorescence in tumors than do the corresponding basic tetrapyrroles. Their use provides the best contrast in tumors compared to normal tissue around the tumor. The instant compounds absorb activating energy for phototherapy in the convenient range of 600 to 800 nanometers, with the preferred compounds absorbing in the 620-760 nanometer range, i.e., light of longer wavelengths which more readily permits penetration of energy into the tumor for phototherapeutic purpose.

In present experience, the present compounds more uniformly distribute throughout the tumor than the basic tetrapyrrole permitting the use of considerably lower dosage (to about 1/10th of the required normal dose of the basic tetrapyrrole) which lessens, if not eliminates, photosensitization in the host. They also possess a more consistent fluorescence whereas some of the corresponding tetrapyrroles show inconsistent fluorescence or the fluorescence varies from day to day in the host.

A particularly advantageous property of the present compounds resides in the ease with which they are excreted by the host. Generally, within 48 to 72 hours of intravenous or intraperitoneal administration, there are little or no detectable amounts in normal muscle tissue. The present compounds which are excreted with their chromophore intact are recovered from the feces of the host within 48-72 hours of injection. Under equivalent circumstances, substantial amounts of the corresponding tetrapyrroles remain, as compared with only minor amounts of peptides formed with the aminocarboxylic acids remain in the host, e.g., up to about 20%. This property is extremely important in that it contributes to minimization of photosensitization of the host.

The instant compositions can be used for diagnosis and therapeutic treatment of a broad range of tumors. Examples of tumors are gastric cancer, enteric cancer, lung cancer, breast cancer, uterine cancer, esophageal cancer, ovarian cancer, pancreatic cancer, pharyngeal cancer, sarcomas, hepatic cancer, cancer of the urinary bladder, cancer of the upper jaw, cancer of the bile duct, cancer of the tongue, cerebral tumor, skin cancer, malignant goiter, prostatic cancer, cancer of the parotid gland, Hodgkin's disease, multiple myeloma, renal cancer, leukemia; and malignant lymphocytoma. For diagnosis, the sole requirement is that the tumor be capable of selectivity fluorescing when exposed to proper light. For treatment, the tumor must be penetrable by the activation energy. For diagnosis, light of shorter wavelength is used whereas for therapeutic purposes light of longer wavelength is used to permit ready penetration of the

tumor tissue. Thus, for diagnosis, light of from 360 - 760 nanometers can be used, and for treatment, from 620 - 760, depending on the individual characteristics of the tetrapyrrole. The absorption characteristics of the present new compounds are substantially the same as the tetrapyrrole from which derived.

It is necessary that the light rays be so intense as to cause the compounds to emit fluorescence for diagnosis and to exert a cell killing effect for therapy.

The source of irradiation for photodiagnosis and phototherapy is not restricted, however, but the laser beam is preferable because intensive light rays in a desired wavelength range can be selectively applied. For example, in photodiagnosis, the compound of the invention is administered to a human or animal body, and after a certain period of time, light rays are applied to the part to be examined. When an endoscope 10 can be used for the affected part, such as lungs, gullet, stomach, womb, urinary bladder or rectum, it is irradiated using the endoscope, and the tumor portion selectively emits fluorescence. This portion is observed visually, or observed through an adapted fiber scope by eye or on a CRT screen.

In phototherapy, after administration of the dosage, the irradiation is carried out by laser beams from the tip of quartz fibers. Besides the irradiation of the surface of tumor, the internal part of the tumor can be 15 irradiated by inserting the tip of quartz fibers into the tumor. The irradiation can be visually observed or imaged on a CRT screen.

For photodiagnosis, light of wavelengths between 360 and 760 nm. is suitable for activating the present tetrapyrrole compounds. Of course, each compound has a specific optimal wavelength of activation. A long wavelength ultraviolet lamp is particularly suitable for photodiagnosis. Similar methods for viewing of the 20 treated tumor can be used as already described for phototherapy.

The dosages of the present compositions will vary depending on the desired effect, whether for diagnosis or for treatment. For diagnosis, doses of as little as 1 mg/kg will be effective, and up to about 20 mg/kg can be used. For treatment, the dose will usually approximate about 0.5 mg/kg. Of course, the dosage for either diagnosis or treatment can be varied widely in view of aforesaid advantageous properties 25 of the present compounds, e.g., the ease of elimination from the host, for one.

The present compositions are apparently non-toxic at the dosage levels employed for diagnosis or treatment. No mortality of test animals due the present compounds has been noted in studies employing dosage levels up to 20 mg/kg.

For both diagnosis and treatment, the present compositions can be administered by the oral, intravenous, or intramuscular routes. They can be formulated as lyophilized sterile, pyrogen-free compounds, 30 preferably in the form of basic salts, e.g., sodium salt. The preferred dosage forms are provided as injectable solutions (isotonic).

The irradiation source used in treatment of tumors containing compounds of this invention is a filter, high-intensity, continuous source or pumped dye, or other laser and light delivery system, which is capable 35 of performing within the following limits: power intensity 20-500 mw/cm<sup>2</sup> at wavelengths between 620 and 700 nm. and a total output of at least 500 mw. or greater. Several currently commercially available lasers meet these criteria.

The tetrapyrroles can be prepared by various synthetic methods which are found in the literature, e.g., Pheophorbides

40 Willstatter, R., Stoll, A.; Investigations on Chlorophyll, (Transl. Schertz, F.M., Merz, A.R.) p. 249. Science Printing Press, Lancaster, Pennsylvania, 1928.

Pennington, F.C. Strain, H.H., Svec, W.A., Katz, J.J.; J. Amer. Chem. Soc., 86, 1418 (1964).

#### Chlorin e<sub>6</sub>

45 Willstatter, R. Stoll, A.; Investigations on Chlorophyll, (Transl., Schertz, F.M., Merz, A.R.) p. 176. Science Printing Press, Lancaster, Pennsylvania, 1928.

Willstatter, R., Isler, M.; Ann. Chem., 390, 269 (1912).

Fisher, H., Baumler, P.; Ann. Chem., 474, 65 (1929).

50 Fisher, H., Siebel, H.; Ann. Chem., 499, 84 (1932).

Conant, J.B., Mayer, W.W.; J. Amer. Chem. Soc., 52, 3013 (1930).

#### Chlorin e<sub>4</sub>

55 Fisher, H., Heckmaier, J., Plotz, E.; Justus Leibigs Ann. Chem., 500, 215 (1933).

Chlorin e<sub>6</sub>, e<sub>4</sub>, isochlorin e<sub>4</sub>, mesochlorin e<sub>6</sub>, bacteriochlorophorbide, bacteriochlorin e<sub>6</sub>

Fischer and Orth, "D's Chemie des Pyrrole" Akademisch Verlagssesellschaft, Leipzig, 1940, Vol. II,  
Part 2.

General Reference for Porphyrins

- 5 "Porphyrins and Metalloporphyrins" ed. Kevin M. Smith, Elsevier 1975 N.Y.  
 The compositions of the present invention can be administered to the host in a variety of forms adapted  
 to the chosen route of administration, i.e., orally, intravenously, intramuscularly or subcutaneous routes.  
 The compositions may be orally administered, for example, with an inert diluent or with an assimilable  
 10 edible carrier, or it may be enclosed in hard or soft shell gelatin capsule, or it may be compressed into  
 tablets, or it may be incorporated directly with the food of the diet. For oral therapeutic administration, the  
 compositions may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets,  
 troches, capsules, elixirs, suspensions, syrups or wafers. Such compositions and preparations should  
 contain at least 0.1% of active compound. The percentage of the compositions and preparations may, of  
 course, be varied and may conveniently be between about 2 to about 60% of the weight of the unit. Th  
 15 amount of active compound in such therapeutically useful compositions is such that a suitable dosage will  
 be obtained. Preferred compositions or preparations according to the present invention are prepared so that  
 an oral dosage unit form contains between about 50 and 300 mg of active compound.  
 The tablets, troches, pills or capsules may also contain the following: A binder such as gum tragacanth,  
 20 acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn  
 starch, potato starch or alginic acid; a lubricant such as sucrose, lactose or saccharin may be added or a  
 flavoring agent such as peppermint, oil of wintergreen, or cherry flavoring. When the dosage unit form is a  
 25 capsule, it may contain, in addition to materials of the above type, a liquid carrier. Various other materials  
 may be present as coatings or to otherwise modify the physical form of the dosage unit. For instanc  
 tablets, pills, or capsules may be coated with shellac, sugar or both. A syrup or elixir may contain the  
 compositions, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and  
 flavoring such as cherry or orange flavor. Of course, any material used in preparing any dosage unit form  
 should be pharmaceutically pure and substantially non-toxic in the amounts employed. In addition, th  
 active compound may be incorporated into sustained-release preparations and formulations.  
 30 The composition may also be administered parenterally or intraperitoneally. Solutions of the composition  
 as a free base or pharmacologically acceptable salt can be prepared in water suitably mixed with a  
 surfactant such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene  
 glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations  
 contain a preservative to prevent the growth of microorganisms.  
 35 The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions  
 and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all  
 cases the form must be sterile and must be fluid to the extent that easy syringability exists. It must be  
 stable under the conditions of manufacture and storage and must be preserved against the contaminating  
 40 action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium  
 containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol or liquid polyethylene  
 glycol), suitable mixtures thereof, and vegetable oils. The proper fluidity can be maintained, for example, by  
 the use of a coating such as lecithin, by the maintenance of the required particle size in the case of  
 dispersion and by the use of surfactants. The prevention of the action of microorganisms can be brought  
 about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic  
 45 acid or thimerosal. In many cases, it will be preferable to include isotonic agents, for example, sugars or  
 sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in  
 the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.  
 Sterile injectable solutions are prepared by incorporating the composition in the required amount in the  
 appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered  
 50 sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredient into  
 a sterile vehicle which contains the basic dispersion medium and the required other ingredients from thos  
 enumerated above. In the cas of sterl powders for the preparation of sterile injectable solutions, th  
 preferred methods of preparation are vacuum drying and the freez -drying technique which yield a powder  
 of the active ingredient plus any additional desired ingredient from previously st rile-filtered solution th reof.  
 55 The present new compositions may also be applied directly to tumors, whether internal or external, in  
 the host in topical compositions. Exemplary compositions include solutions of th new compounds in  
 solvents, particularly aqueous solvents, most preferably water. Alternatively, for topical application particu  
 larly to skin tumors, the present new compounds may be dispersed in the usual cream or salve-formulations

commonly used for this purpose or may be provided in the form of spray solutions or suspensions which may include a propellant usually employed in aerosol preparations.

As used herein, "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents or isotonic and absorption delaying agents. The use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.

It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the mammalian subjects to be treated; each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the novel dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the active material and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such an active material for the treatment of tumors in living subjects.

The following examples further illustrate the invention.

#### Mono-, di and Triamides:

#### EXAMPLE 1

##### Di and mono(DL) serinyl mesoporphyrin IX (mixed anhydrides method)

400 mg (0.0007 moles) of mesoporphyrin IX were suspended in 50 ml of tetrahydrofuran (THF). 360  $\mu$ l (0.0035 moles) of triethylamine were added with stirring. After 10 minutes, 340  $\mu$ l (0.0031 moles) ethyl chloroformate were added. After stirring 10 minutes, 10 ml (0.01 moles) of 1 M KOH containing 761 mg (0.0072 moles) of DL serine were added to the THF solution. This mixture was stirred 60 minutes at room temperature.

The organic solvent was flashed off and the reaction mixture was checked by silica TLC for product. Benzene/methanol/88% formic acid (8.5/1.5/0.13) was used to develop the chromatogram.

After checking for product, the solution was adjusted to pH 7.5-8.0 and placed on a reverse phase (C-18 silica) column 2.5 x 30 cm. The reaction mixture was resolved using a linear gradient of 20-70% methanol in 0.01 M KPO<sub>4</sub> buffer pH 6.85 (1 liter total volume).

The column effluent was collected via fraction collector and the tube contents were pooled according to individual components. The order of elution was di-DL-serinyl mesoporphyrin IX, mono-DL-serinyl mesoporphyrin IX and unsubstituted mesoporphyrin IX.

The methanol was flashed off and the material was precipitated at pH 2.5-3.0. The ppt. was washed 3 times with dilute acetic acid in water. The product was dried under vacuum. The yield of di (DL) serinyl mesoporphyrin IX was 95.6 mg.

40

#### EXAMPLE 2

##### Di and mono glycyl mesoporphyrin IX (mixed anhydride method)

100 mg (0.000175 moles) of mesoporphyrin IX were suspended in 100 ml of tetrahydrofuran (THF). 360  $\mu$ l (0.0035 moles) of triethylamine were added with stirring. After 10 minutes, 340  $\mu$ l (0.0031 moles) of ethylchloroformate were added. After stirring 10 minutes, 10 ml (0.01 moles) of 1M KOH containing 500 mg (0.0066 moles) of glycine were added to the THF solution. This mixture was stirred 60 minutes at room temperature.

The organic solvent was flashed off and the reaction mixture was checked by silica TLC for product. Benzene/methanol/88% formic acid (8.5/1.5/0/13) was used to develop the chromatogram.

After checking for product, the solution was adjusted to pH 7.5-8.0 and placed on a reverse phase (C-18 silica) column 2.5 x 30 cm. The reaction mixture was resolved using a linear gradient of zero to 50% methanol in 0.01 M KPO<sub>4</sub> buffer pH 6.85 (1 l total volume).

The column effluent was collected in a fraction collector and the contents were sorted according to individual components. The order of elution was diglycyl mesoporphyrin IX, monoglycyl mesoporphyrin IX and unsubstituted mesoporphyrin IX.

The methanol was flashed off and the material was precipitated at pH 2.5-3.0. The ppt. was washed 3

times with dilute acetic acid in water. The product was dried under vacuum.

#### EXAMPLE 3

##### 5 Di and Mono $\alpha$ (DL) alanyl mesoporphyrin IX (mixed anhydride method)

100 mg (0.000175 moles) of mesoporphyrin IX were suspended in 100 ml of tetrahydrofuran (THF). 210  $\mu$ l (0.002 moles) of triethylamine were added with stirring. After 10 minutes 195  $\mu$ l (0.00177 moles) of ethylchloroformate were added. After stirring 10 minutes, 10 ml (0.01 moles) of 1M KOH containing 500 mg (0.0056 moles) of  $\alpha$  (DL) alanine were added to the THF solution. This mixture was stirred 60 minutes at room temperature.

The organic solvent was flashed off and the reaction mixture was checked by silica TLC for product. Benzene/methanol/88% formic acid (8.5/1.5/0.13) was used to develop the chromatogram.

After checking for product, the solution was adjusted to pH 7.5-8.0 and placed on a reverse phase (C-18 silica) column 2.5 x 30 cm. The reaction mixture was resolved using a linear gradient of 20-70% methanol in 0.01 M KPO<sub>4</sub> buffer pH 6.85 (1 l total volume).

The column effluent was collected via fraction collection and the tube contents were sorted according to individual components. The order of elution was di- $\alpha$ (DL) alanyl mesoporphyrin IX, mono-  $\alpha$ (DL)-alanyl mesoporphyrin IX and unsubstituted mesoporphyrin IX.

20 The methanol was flashed off and the material was precipitated at pH 2.5-3.0. The ppt. was washed 3 times with dilute acetic acid in water. The product was dried under vacuum.

#### EXAMPLE 4

##### 25 Di and mono $\beta$ alanyl mesoporphyrin IX (mixed anhydride method)

400 mg (0.0007 moles) of mesoporphyrin IX were suspended in 100 ml of tetrahydrofuran (THF). 360  $\mu$ l (0.0035 moles) of triethylamine were added with stirring. After 10 minutes, 340  $\mu$ l (0.0031 moles) ethyl chloroformate were added. After stirring 10 minutes, 10 ml (0.01 moles) of 1 M KOH containing 400 mg (0.0044 moles) of  $\beta$  alanine were added to the THF solution. This mixture was stirred 60 minutes at room temperature.

The organic solvent was flashed off and the reaction mixture was checked by silica TLC for product. Benzene/methanol/88% formic acid (8.5/1.5/0.13) was used to develop the chromatogram.

After checking for product, the solution was adjusted to pH 7.5-8.0 and placed on a reverse phase (C-18 silica) column 2.5 x 30 cm. The reaction mixture was resolved using a linear gradient of 40-50% methanol in 0.01 M KPO<sub>4</sub> buffer pH 6.85 (1 l total volume).

The column effluent was collected via fraction collector and the tube contents were pooled according to individual components. The order of elution was di- $\beta$ -alanyl mesoporphyrin IX, mono- $\beta$ -alanyl mesoporphyrin IX, and unsubstituted mesoporphyrin IX.

40 The methanol was flashed off and the material was precipitated at pH 2.5-3.0. The ppt. was washed 3 times with dilute acetic acid in water. The product was dried under vacuum. The yield for di- $\beta$ -alanyl mesoporphyrin IX was 40 mg; the yield for mono- $\beta$ -alanyl mesoporphyrin IX was 23 mg.

#### EXAMPLE 5

45

##### Di and mono $\epsilon$ amino-n-caproyl mesoporphyrin IX (mixed anhydride method)

400mg (0.0007 moles) of mesoporphyrin IX were suspended in 50 ml of tetrahydrofuran (THF). 360  $\mu$ l (0.0035 moles) of triethylamine were added with stirring. After 10 minutes, 340  $\mu$ l (0.0031 moles) of ethylchloroformate were added. After stirring 10 minutes, 10 ml (0.01 moles) of 1M KOH containing 543 mg (0.00414 moles) of  $\epsilon$ -amino-n-caproic acid were added to the THF solution. This mixture was stirred 60 minutes at room temperature.

The organic solvent was flashed off and the reaction mixture was checked by silica TLC for product. Benzene/methanol/88% formic acid (8.5/1.5/0.13) was used to develop the chromatogram.

55 After checking for product, the solution was adjusted to pH 7.5-8.0 and placed on a reverse phase (C-18 silica) column 2.5x30 cm. The reaction mixture was resolved using a linear gradient of 20-70% methanol in 0.01 M KPO<sub>4</sub> buffer pH 6.85 (1 l total volume).

The column effluent was collected via fraction collector and the tube contents were pooled according to

individual components. The order of elution was di- $\epsilon$ -amino-n-caproyl mesoporphyrin IX, mono- $\epsilon$ -amino-n-caproyl mesoporphyrin IX, and unsubstituted mesoporphyrin IX.

The methanol was flashed off and the material was precipitated at pH 2.5-3.0. The ppt. was washed three times with dilute acetic acid in water. The product was dried under vacuum. The yield of di- $\epsilon$ -amino-n-caproyl mesoporphyrin IX was 237 mg.

#### EXAMPLE 6

##### Di and mono- $\beta$ -alanyl hematoporphyrin IX (mixed anhydride method)

400 mg (0.00059 moles) of hematoporphyrin IX dihydrochloride were suspended in 50 ml of tetrahydrofuran (THF).

360 $\mu$ l (0.0035 moles) of triethylamine were added with stirring. After 10 minutes, 340 $\mu$ l (0.0031 moles) of ethyl chloroformate were added. After stirring 10 minutes, 10 ml (0.01 moles) of 1M KOH containing 400 mg (0.0044 moles) of  $\beta$  alanine were added to the THF solution. This mixture was stirred 60 minutes at room temperature.

The organic solvent was removed by flash evaporation, keeping the temperature below 50°C. The reaction mixture was checked for product by silica TLC using Benzene/methanol/88% formic acid (8.5/1.5/0.13) as solvent to develop the chromatogram.

The solution was adjusted to pH 7.5-8.0 with HCl and placed on a reverse phase (C-18 silica) column 2.5 x 30 cm. The mixture was resolved using a linear gradient of 40-80% methanol in 0.01M KPO<sub>4</sub> buffer pH 6.85 (1 liter total volume). The individual components were collected as they came off the column in the order di- $\beta$ -alanyl hematoporphyrin IX, mono- $\beta$ -alanyl hematoporphyrin IX and hematoporphyrin IX.

The methanol was removed from each component by flash evaporation and the material was precipitated by adjusting the pH to 2.5 - 3.0 using HCl. The precipitate was washed three times with dilute acetic acid in water at the centrifuge and the products dried under vacuum. The yield of di- $\beta$ -alanyl hematoporphyrin IX was 52mg and of mono- $\beta$ -alanyl hematoporphyrin was 30 mg.

#### EXAMPLE 7

##### Di-L- $\alpha$ -Serinyl chlorin e<sub>6</sub> (mixed anhydride method)

650 mg of chlorin e<sub>6</sub> were dissolved in 30 ml of dimethylformide (DMF). 227  $\mu$ l (0.002 moles) of triethylamine were added to the DMF solution. After stirring for five minutes, 201  $\mu$ l (0.002 moles) of ethyl chloroformate were added and stirring was continued for an additional 30 minutes. 0.95 g (0.009 moles) of L- $\alpha$ -serine were added to the DMF solution and allowed to stir for one hour at 50-60°C.

The DMF solution was checked for product formation by reverse phase (C-18 silica) TLC using methanol/0.01 M sodium phosphate buffer, pH 6.85, (7.0/3.0) to develop the chromatogram. The DMF solution was flash evaporated to near dryness and the reaction mixture was then taken up in dilute NaOH and the pH was adjusted to 2.5-3.0 to precipitate out the mixture. The precipitate was then centrifuged down and washed twice with diluted acetic acid in water. The precipitate was then centrifuged down and washed twice with diluted acetic acid in water. The precipitate was then redissolved in dilute NaOH and the pH adjusted to 7.0. This was applied to a reverse phase (C-18 silica) column 3.7 cm x 45 cm.

The product was eluted from the column with a solution of 0.01M sodium phosphate buffer, pH 6.85/methanol (7.0/3.0). Fractions were collected and the fractions of pure di-L- $\alpha$ -serinyl chlorin e<sub>6</sub> were pooled. The methanol was flashed off and the product was precipitated at pH 2.5-3.0. The precipitate was centrifuged down, washed three times with dilute acetic acid, and dried under vacuum. The yield was 200 mg of di-L- $\alpha$ -serinyl chlorin e<sub>6</sub>.

Utilizing the aforementioned carbodiimide or the mixed anhydride methods, the following preferred compounds of this invention can be synthesized:

#### 55 Chlorin Derivatives

Di - (DL)-serinyl-trans-mesochlorin IX  
Di - glycyl-trans-mesochlorin IX

- Di- $\alpha$ -(DL)-alanyl-trans-mesochlorin IX  
 Di- $\beta$ -alanyl-trans-mesochlorin IX  
 Di- $\epsilon$ -amino-n-caproyl-mesochlorin IX  
 Di-, tri- (D,L)-serinyl chlorin e<sub>6</sub>  
 5 Di, tri- (D,L)-serinyl mesochlorin e<sub>6</sub>  
 Di, tri- glycyl chlorin e<sub>6</sub>  
 Di, tri- glycyl mesochlorin e<sub>6</sub>  
 Di, tri- $\alpha$ -(D,L)-alanyl chlorin e<sub>6</sub>  
 Di, tri- $\alpha$ -(D,L)-alanyl mesochlorin e<sub>6</sub>  
 10 Di, tri- $\beta$ -alanyl chlorin e<sub>6</sub>  
 Di, tri- $\beta$ -alanyl mesochlorin e<sub>6</sub>  
 Di, tri- $\epsilon$ -amino-n-caproyl chlorin e<sub>6</sub>  
 Di, tri- $\epsilon$ -amino-n-caproyl mesochlorin e<sub>6</sub>  
 Di- (D,L)-serinyl chlorin e<sub>4</sub>  
 15 Di- (D,L)-serinyl mesochlorin e<sub>4</sub>  
 Di- (D,L)-serinyl isochlorin e<sub>4</sub>  
 Di- (D,L)-serinyl mesoisochlorin e<sub>4</sub>  
 Di- glycyl chlorin e<sub>4</sub>  
 Di- glycyl mesochlorin e<sub>4</sub>  
 20 Di- glycyl isochlorin e<sub>4</sub>  
 Di- glycyl mesoisochlorin e<sub>4</sub>  
 Di- $\alpha$ -(DL)-alanyl chlorin e<sub>4</sub>  
 Di- $\alpha$ -(DL)-alanyl mesochlorin e<sub>4</sub>  
 Di- $\alpha$ -(DL)-alanyl isochlorin e<sub>4</sub>  
 25 Di- $\alpha$ -(DL)-alanyl mesoisochlorin e<sub>4</sub>  
 Di- $\beta$ -alanyl chlorin e<sub>4</sub>  
 Di- $\beta$ -alanyl mesochlorin e<sub>4</sub>  
 Di- $\beta$ -alanyl isochlorin e<sub>4</sub>  
 Di- $\beta$ -alanyl mesoisochlorin e<sub>4</sub>  
 30 Di- $\epsilon$ -amino-n-caproyl chlorin e<sub>4</sub>  
 Di- $\epsilon$ -amino-n-caproyl mesochlorin e<sub>4</sub>  
 Di- $\epsilon$ -amino-n-caproyl isochlorin e<sub>4</sub>  
 Di- $\epsilon$ -amino-n-caproyl mesoisochlorin e<sub>4</sub>  
 Di- (D,L)-serinylphotoporphyrin IX  
 35 Di- glycylphotoporphyrin IX  
 Di- $\alpha$ -(D,L)-alanylphotoporphyrin IX  
 Di- $\beta$ -alanylphotoporphyrin IX  
 Di- $\epsilon$ -amino-n-caproylphotoporphyrin IX

40 Porphyrin Derivatives

- Di- (D,L)-serinylmesoporphyrin IX  
 Di- glycylmesoporphyrin IX  
 Di- $\alpha$ -(DL)-alanylmesoporphyrin IX  
 45 Di- $\beta$ -alanylmesoporphyrin IX  
 Di- $\epsilon$ -amino-n-caproylmesoporphyrin IX  
 Di-(D,L)-serinylprotoporphyrin IX  
 Di-glycylprotoporphyrin IX  
 Di- $\alpha$ -(D,L)-alanylprotoporphyrin IX  
 50 Di- $\beta$ -alanylprotoporphyrin IX  
 Di- $\epsilon$ -amino-n-caproylprotoporphyrin IX  
 Di-(D,L)-serinyldeuteroporphyrin IX  
 Di-glycyldeuteroporphyrin IX  
 Di- $\alpha$ -(D,L)-alanyldeuteroporphyrin IX  
 55 Di- $\beta$ -alanyldeuteroporphyrin IX  
 Di- $\epsilon$ -amino-n-caproyldeuteroporphyrin IX  
 Di, tri, tetra- (D,L)-serinylcoproporphyrin III  
 Di, tri, tetra- glycylcoproporphyrin III

Di, tri, tetra- $\alpha$ -(D,L)-alanylcoproporphyrin III  
 Di, tri, tetra- $\beta$ -alanylcoproporphyrin III  
 Di, tri, tetra- $\epsilon$ -amino-n-caproylcoproporphyrin III  
 Di-(D,L)-serinylhematoporphyrin IX  
 5 Di-glycylhematoporphyrin IX  
 Di- $\alpha$ -(D,L)-alanylhematoporphyrin IX  
 Di- $\beta$ -alanylhematoporphyrin IX  
 Di- $\epsilon$ -amino-n-caproylhematoporphyrin IX

**10 Bacteriochlorin Derivatives**

Di-(D,L)-serinylbacteriochlorin e<sub>4</sub>  
 Di-glycylbacteriochlorin e<sub>4</sub>  
 Di- $\alpha$ -(D,L)-alanylbacteriochlorin e<sub>4</sub>  
 15 Di- $\beta$ -alanylbacteriochlorin e<sub>4</sub>  
 Di- $\epsilon$ -amino-n-caproylbacteriochlorin e<sub>4</sub>  
 Di-(D,L)-serinylbacterioisochlorin e<sub>4</sub>  
 Di-glycylbacterioisochlorin e<sub>4</sub>  
 Di- $\alpha$ -(D,L)-alanylbacterioisochlorin e<sub>4</sub>  
 20 Di- $\beta$ -alanylbacterioisochlorin e<sub>4</sub>  
 Di- $\epsilon$ -amino-n-caproylbacterioisochlorin e<sub>4</sub>  
 Di, tri- (D,L)-serinylbacteriochlorin e<sub>6</sub>  
 Di, tri- glycylbacteriochlorin e<sub>6</sub>  
 Di, tri- $\alpha$ -(D,L)-alanylbacteriochlorin e<sub>6</sub>  
 25 Di, tri- $\beta$ -alanylbacteriochlorin e<sub>6</sub>  
 Di, tri- $\epsilon$ -amino-n-caproylbacteriochlorin e<sub>6</sub>

Similarly, by utilizing other amino acids, peptides which further illustrate embodiments of, but do not limit the present invention, can be employed:

Di-threoninyl trans-mesochlorin IX  
 30 Di,tri-threoninyl chlorin e<sub>6</sub>  
 Di,tri-threoninyl mesochlorin e<sub>6</sub>  
 Di-threoninyl chlorin e<sub>4</sub>  
 Di-threoninyl mesochlorin e<sub>4</sub>  
 Di-threoninyl isochlorin e<sub>4</sub>  
 35 Di-threoninyl mesoisochlorin e<sub>4</sub>  
 Di-threoninyl photoprotoporphyrin IX  
 Di-threoninyl mesoporphyrin IX  
 Di-threoninyl protoporphyrin IX  
 Di-threoninyl deuteroporphyrin IX  
 40 Di,tri,tetra-threoninyl coproporphyrin III  
 Di-threoninyl hematoporphyrin IX  
 Di-threoninyl bacteriochlorin e<sub>4</sub>  
 Di-threoninyl bacterioisochlorin e<sub>4</sub>  
 Di,tri-threoninyl bacteriochlorin e<sub>6</sub>  
 45 Di-cysteinyl trans-mesochlorin IX  
 Di,tri-cysteinyl chlorin e<sub>6</sub>  
 Di,tri-cysteinyl mesochlorin e<sub>6</sub>  
 Di-cysteinyl chlorin e<sub>4</sub>  
 Di-cysteinyl isochlorin e<sub>4</sub>  
 50 Di-cysteinyl mesoisochlorin e<sub>4</sub>  
 Di-cysteinyl photoprotoporphyrin IX  
 Di-cysteinyl mesoporphyrin IX  
 Di-cysteinyl protoporphyrin IX  
 Di-cysteinyl deuteroporphyrin IX  
 55 Di,tri,tetra-cysteinyl-coproporphyrin III  
 Di-cysteinyl hematoporphyrin IX  
 Di-cysteinyl bacteriochlorin e<sub>4</sub>  
 Di-cysteinyl bacterioisochlorin e<sub>4</sub>

- Di, tri-cysteinyl bacteriochlorin e<sub>6</sub>  
 Di-tyrosyl trans-mesochlorin IX  
 Di, tri-tyrosyl chlorin e<sub>6</sub>  
 Di,tri-tyrosyl mesochlorin e<sub>6</sub>  
 5 Di-tyrosyl chlorin e<sub>4</sub>  
 Di-tyrosyl mesochlorin e<sub>4</sub>  
 Di-tyrosyl isochlorin e<sub>4</sub>  
 Di-tyrosyl mesoisochlorin e<sub>4</sub>  
 Di-tyrosyl photoprotoporphyrin IX  
 10 Di-tyrosyl mesoporphyrin IX  
 Di-tyrosyl protoporphyrin IX  
 Di-tyrosyl deuteroporphyrin IX  
 Di,tri,tetra-tyrosyl coproporphyrin III  
 Di-tyrosyl hematoporphyrin IX  
 15 Di-tyrosyl bacteriochlorin e<sub>4</sub>  
 Di-tyrosyl bacterioisochlorin e<sub>4</sub>  
 Di,tri-tyrosyl bacteriochlorin e<sub>6</sub>  
 Di-valyl trans-mesochlorin IX  
 Di,tri-valyl chlorin e<sub>6</sub>  
 20 Di,tri-valyl mesochlorin e<sub>6</sub>  
 Di-valyl chlorin e<sub>4</sub>  
 Di-valyl mesochlorin e<sub>4</sub>  
 Di-valyl isochlorin e<sub>4</sub>  
 Di-valyl mesoisochlorin e<sub>4</sub>  
 25 Di-valyl photoprotoporphyrin IX  
 Di-valyl mesoporphyrin IX  
 Di-valyl protoporphyrin IX  
 Di-valyl deuteroporphyrin IX  
 Di,tri,tetra-valyl coproporphyrin III  
 30 Di-valyl hematoporphyrin IX  
 Di-valyl bacteriochlorin e<sub>4</sub>  
 Di-valyl bacterioisochlorin e<sub>4</sub>  
 Di,tri-valyl bacteriochlorin e<sub>6</sub>  
 Di-leucyl trans-mesochlorin IX  
 35 Di,tri-leucyl chlorin e<sub>6</sub>  
 Di,tri-leucyl mesochlorin e<sub>6</sub>  
 Di-leucyl chlorin e<sub>4</sub>  
 Di-leucyl mesochlorin e<sub>4</sub>  
 Di-leucyl isochlorin e<sub>4</sub>  
 40 Di-leucyl mesoisochlorin e<sub>4</sub>  
 Di-leucyl photoprotoporphyrin IX  
 Di-leucyl mesoporphyrin IX  
 Di-leucyl protoporphyrin IX  
 Di-leucyl deuteroporphyrin IX  
 45 Di,tri,tetra-leucyl coproporphyrin III  
 Di-leucyl hematoporphyrin IX  
 Di-leucyl bacteriochlorin e<sub>4</sub>  
 Di-leucyl bacterioisochlorin e<sub>4</sub>  
 Di,tri-leucyl bacteriochlorin e<sub>6</sub>  
 50 Di-isoleucyl trans-mesochlorin IX  
 Di,tri-isoleucyl chlorin e<sub>6</sub>  
 Di,tri-isoleucyl mesochlorin e<sub>6</sub>  
 Di-isoleucyl chlorin e<sub>4</sub>  
 Di-isoleucyl mesochlorin e<sub>4</sub>  
 55 Di-isoleucyl isochlorin e<sub>4</sub>  
 Di-isoleucyl mesoisochlorin e<sub>4</sub>  
 Di-isoleucyl photoprotoporphyrin IX  
 Di-isoleucyl mesoporphyrin IX

- Di-isoleucyl protoporphyrin IX  
 Di-isoleucyl deuteroporphyrin IX  
 Di,tri,t tra-isoleucyl coproporphyrin III  
 Di-isoleucyl hematoporphyrin IX  
 5 Di-isoleucyl bacteriochlorin e<sub>4</sub>  
 Di-isoleucyl bacterioisochlorin e<sub>4</sub>  
 Di,tri-isoleucyl bacteriochlorin e<sub>6</sub>  
 Di-prolyl trans-mesochlorin IX  
 Di,tri-prolyl chlorin e<sub>6</sub>  
 10 Di,tri-prolyl mesochlorin e<sub>6</sub>  
 Di-prolyl chlorin e<sub>4</sub>  
 Di-prolyl mesochlorin e<sub>4</sub>  
 Di-prolyl isochlorin e<sub>4</sub>  
 Di-prolyl mesoischlorin e<sub>4</sub>  
 15 Di-prolyl photoporphyrin IX  
 Di-prolyl mesoporphyrin IX  
 Di-prolyl protoporphyrin IX  
 Di-prolyl deuteroporphyrin IX  
 Di,tri,tetra-prolyl coproporphyrin III  
 20 Di-prolyl hematoporphyrin IX  
 Di-prolyl bacteriochlorin e<sub>4</sub>  
 Di-prolyl bacteriosochlorin e<sub>4</sub>  
 Di,tri-prolyl bacteriochlorin e<sub>6</sub>  
 Di-phenylalanyl trans-mesochlorin IX  
 25 Di,tri-phenylalanyl chlorin e<sub>6</sub>  
 Di,tri-phenylalanyl mesochlorin e<sub>6</sub>  
 Di-phenylalanyl chlorin e<sub>4</sub>  
 Di-phenylalanyl mesochlorin e<sub>4</sub>  
 Di-phenylalanyl isochlorin e<sub>4</sub>  
 30 Di-phenylalanyl mesoischlorin e<sub>4</sub>  
 Di-phenylalanyl photoporphyrin IX  
 Di-phenylalanyl mesoporphyrin IX  
 Di-phenylalanyl protoporphyrin IX  
 Di-phenylalanyl deuteroporphyrin IX  
 35 Di,tri,tetra-phenylalanyl coproporphyrin III  
 Di-phenylalanyl hematoporphyrin IX  
 Di-phenylalanyl bacteriochlorin e<sub>4</sub>  
 Di-phenylalanyl bacteriosochlorin e<sub>4</sub>  
 Di,tri-phenylalanyl bacteriochlorin e<sub>6</sub>  
 40 Di-tryptophyl trans-mesochlorin IX  
 Di,tri-tryptophyl chlorin e<sub>6</sub>  
 Di,tri-tryptophyl mesochlorin e<sub>6</sub>  
 Di-tryptophyl chlorin e<sub>4</sub>  
 Di-tryptophyl mesochlorin e<sub>4</sub>  
 45 Di-tryptophyl isochlorin e<sub>4</sub>  
 Di-tryptophyl mesoischlorin e<sub>4</sub>  
 Di-tryptophyl photoporphyrin IX  
 Di-tryptophyl mesoporphyrin IX  
 Di-tryptophyl protoporphyrin IX  
 50 Di-tryptophyl deuteroporphyrin IX  
 Di,tri,tetra-tryptophyl coproporphyrin III  
 Di-tryptophyl hematoporphyrin IX  
 Di-tryptophyl bacteriochlorin e<sub>4</sub>  
 Di-tryptophyl bacteriosochlorin e<sub>4</sub>  
 55 Di,tri-tryptophyl bacteriochlorin e<sub>6</sub>  
 Di-methionyl trans-mesochlorin IX  
 Di,tri-methionyl chlorin e<sub>6</sub>  
 Di,tri-methionyl mesochlorin e<sub>6</sub>

- Di-methionyl chlorin
- Di-methionyl mesochlorin e<sub>4</sub>
- Di-methionyl isochlorin e<sub>4</sub>
- Di-methionyl mesoisochlorin e<sub>4</sub>
- 5 Di-methionyl photoporphyrin IX
- Di-methionyl mesoporphyrin IX
- Di-methionyl protoporphyrin IX
- Di-methionyl deuteroporphyrin IX
- Di,tri,tetra-methionyl coproporphyrin III
- 10 Di-methionyl hematoporphyrin IX
- Di-methionyl bacteriochlorin e<sub>4</sub>
- Di-methionyl bacterioisochlorin e<sub>4</sub>
- Di,tri-methionyl bacteriochlorin e<sub>6</sub>
- Di-histidyl trans-mesochlorin IX
- 15 Di,tri-histidyl Chlorin e<sub>6</sub>
- Di,tri-histidyl mesochlorin e<sub>6</sub>
- Di-histidyl chlorin e<sub>4</sub>
- Di-histidyl mesochlorin e<sub>4</sub>
- Di-histidyl isochlorin e<sub>4</sub>
- 20 Di-histidyl mesoisochlorin e<sub>4</sub>
- Di-histidyl photoporphyrin IX
- Di-histidyl mesoporphyrin IX
- Di-histidyl protoporphyrin IX
- Di-histidyl deuteroporphyrin IX
- 25 Di tri,tetra-histidyl coproporphyrin III
- Di-histidyl hematoporphyrin IX
- Di-histidyl bacteriochlorin e<sub>4</sub>
- Di-histidyl bacterioisochlorin e<sub>4</sub>
- Di,tri-histidyl bacteriochlorin e<sub>6</sub>
- 30 Di-arginyl trans-mesochlorin IX
- Di,tri-arginyl chlorin e<sub>6</sub>
- Di,tri-arginyl mesochlorin e<sub>6</sub>
- Di-arginyl chlorin e<sub>4</sub>
- Di-arginyl mesochlorin e<sub>4</sub>
- 35 Di-arginyl isochlorin e<sub>4</sub>
- Di-arginyl mesoisochlorin e<sub>4</sub>
- Di-arginyl photoporphyrin IX
- Di-arginyl mesoporphyrin IX
- Di-arginyl protoporphyrin IX
- 40 Di-arginyl deuteroporphyrin IX
- Di,tri,tetra-arginyl coproporphyrin III
- Di-arginyl hematoporphyrin IX
- Di-arginyl bacteriochlorin e<sub>4</sub>
- Di-arginyl bacterioisochlorin e<sub>4</sub>
- 45 Di,tri-arginyl bacteriochlorin e<sub>6</sub>
- Di-lysyl trans-mesochlorin IX
- Di,tri-lysyl chlorin e<sub>6</sub>
- Di,tri-lysyl mesochlorin e<sub>6</sub>
- Di-lysyl chlorin e<sub>4</sub>
- 50 Di-lysyl mesochlorin e<sub>4</sub>
- Di-lysyl isochlorin e<sub>4</sub>
- Di-lysyl mesoisochlorin e<sub>4</sub>
- Di-lysyl photoporphyrin IX
- Di-lysyl mesoporphyrin IX
- 55 Di-lysyl protoporphyrin IX
- Di-lysyl deuteroporphyrin IX
- Di,tri,tetra-lysyl coproporphyrin III
- Di-lysyl hematoporphyrin IX

- Di-lysyl bacteriochlorin e<sub>4</sub>  
 Di-lysyl bacterioisochlorin e<sub>4</sub>  
 Di,tri-lysyl bacteriochlorin e<sub>5</sub>  
 Di-glutamyl trans-m sochlorin IX  
 5 Di,tri-glutamyl chlorin e<sub>6</sub>  
 Di,tri-glutamyl mesochlorin e<sub>6</sub>  
 Di-glutamyl chlorin e<sub>4</sub>  
 Di-glutamyl mesochlorin e<sub>4</sub>  
 Di-glutamyl isochlorin e<sub>4</sub>  
 10 Di-glutamyl mesoisochlorin e<sub>4</sub>  
 Di-glutamyl photoporphyrin IX  
 Di-glutamyl mesoporphyrin IX  
 Di-glutamyl protoporphyrin IX  
 Di-glutamyl deuteroporphyrin IX  
 15 Di,tri,tetra-glutamyl coproporphyrin III  
 Di-glutamyl hematoporphyrin IX  
 Di-glutamyl bacteriochlorin e<sub>4</sub>  
 Di-glutamyl bacterioisochlorin e<sub>4</sub>  
 Di,tri-glutamyl bacteriochlorin e<sub>5</sub>  
 20 Di-asparginyt trans-mesochlorin IX  
 Di,tri-asparginyt chlorin e<sub>6</sub>  
 Di,tri-asparginyt mesochlorin e<sub>6</sub>  
 Di-asparginyt chlorin e<sub>4</sub>  
 Di-asparginyt mesochlorin e<sub>4</sub>  
 25 Di-asparginyt isochlorin e<sub>4</sub>  
 Di-asparginyt mesoisochlorin e<sub>4</sub>  
 Di-asparginyt photoporphyrin IX  
 Di-asparginyt mesoporphyrin IX  
 Di-asparginyt protoporphyrin IX  
 30 Di-asparginyt deuteroporphyrin IX  
 Di,tri,tetra-asparginyt coproporphyrin III  
 Di-asparginyt hematoporphyrin IX  
 Di-asparginyt bacteriochlorin e<sub>4</sub>  
 Di-asparginyt bacterioisochlorin e<sub>4</sub>  
 35 Di,tri-asparginyt bacteriochlorin e<sub>5</sub>

MonoamidesEXAMPLE 8

- 40 Mono (DL) serinyl mesoporphyrin IX (mixed anhydride method)

400 mg (0.0007 moles) of mesoporphyrin IX were suspended in 50 ml of tetrahydrofuran (THF). 360 µl (0.0035 moles) of triethylamine were added with stirring. After 10 minutes, 340 µl (0.0031 moles) ethyl 45 chloroformate were added. After stirring 10 minutes, 10 ml (0.01 moles) of 1 M KOH containing 761 mg (0.0072 moles) of DL serine were added to the THF solution. This mixture was stirred 60 minutes at room temperature.

The organic solvent was flashed off and the reaction mixture was checked by silica TLC for product. Benzene/methanol/88% formic acid (8.5/1.5/0.13) was used to develop the chromatogram.

50 After checking for product, the solution was adjusted to pH 7.5-8.0 and placed on a reverse phase (C-18 silica) column 2.5 × 30 cm. The reaction mixture was resolved using a linear gradient of 20-70% methanol in 0.01 M KPO<sub>4</sub> buffer pH 6.85 (1 liter total volume).

55 The column effluent was collected via fraction collector and the tube contents were pooled according to individual components. The order of elution was diserinyl mesoporphyrin IX, monoserinyl mesoporphyrin IX and unsubstituted mesoporphyrin IX.

The methanol was flashed off and the material was precipitated at pH 2.5-3.0. The ppt. was washed 3 times with dilute acetic acid in water. The product was dried under vacuum.

Example 9Mono glycyl mesoporphyrin IX (mixed anhydride method)

5        100 mg (0.000175 moles) of mesoporphyrin IX were suspended in 100 ml of tetrahydrofuran (THF). 360  $\mu$ l (0.0035 moles) of triethylamine were added with stirring. After 10 minutes, 340  $\mu$ l (0.0031 moles) of ethylchloroformate were added. After stirring 10 minutes, 10 ml (0.01 moles) of 1M KOH containing 500 mg (0.0066 moles) of glycine were added to the THF solution. This mixture was stirred 60 minutes at room temperature.

10      The organic solvent was flashed off and the reaction mixture was checked by silica TLC for product. Benzene/methanol/88% formic acid (8.5/1.5/0.13) was used to develop the chromatogram.

After checking for product, the solution was adjusted to pH 7.5-8.0 and placed on a reverse phase (C-18 silica) column 2.5 x 30 cm. The reaction mixture was resolved using a linear gradient of zero to 50% methanol in 0.01 M KPO<sub>4</sub> buffer pH 6.85 (1 l total volume).

15      The column effluent was collected in a fraction collector and the contents were sorted according to individual components. The order of elution was diglycyl mesoporphyrin IX, monoglycyl mesoporphyrin IX and unsubstituted mesoporphyrin IX.

The methanol was flashed off and the material was precipitated at pH 2.5-3.0. The ppt. was washed 3 times with dilute acetic acid in water. The product was dried under vacuum.

20

EXAMPLE 10Mono  $\alpha$  (DL) alanyl mesoporphyrin IX (Mixed anhydride method)

25      100 mg (0.000175 moles) of mesoporphyrin IX were suspended in 100 ml of tetrahydrofuran (THF). 210  $\mu$ l (0.002 moles) of triethylamine were added with stirring. After 10 minutes 195  $\mu$ l (0.00177 moles) of ethylchloroformate were added. After stirring 10 minutes, 10 ml (0.01 moles) of 1M KOH containing 500 mg (0.0056 moles) of  $\alpha$ (DL) alanine were added to the THF solution. This mixture was stirred 60 minutes at room temperature.

30      The organic solvent was flashed off and the reaction mixture was checked by silica TLC for product. Benzene/methanol/88% formic acid (8.5/1.5/0.13) was used to develop the chromatogram.

After checking for product, the solution was adjusted to pH 7.5-8.0 and placed on a reverse phase (C-18 silica) column 2.5 x 30 cm. The reaction mixture was resolved using a linear gradient of 20-70% methanol in 0.01 M KPO<sub>4</sub> buffer pH 6.85 (1 l total volume).

35      The column effluent was collected via fraction collection and the tube contents were sorted according to individual components. The order of elution was di- $\alpha$ (DL) alanyl mesoporphyrin IX, mono-  $\alpha$ (DL)-alanyl mesoporphyrin IX and unsubstituted mesoporphyrin IX.

The methanol was flashed off and the material was precipitated at pH 2.5-3.0. The ppt. was washed 3 times with dilute acetic acid in water. The product was dried under vacuum.

40

EXAMPLE 11Mono  $\beta$  alanyl mesoporphyrin IX (mixed anhydride method)

45      400 mg (0.0007 moles) of mesoporphyrin IX were suspended in 100 ml of tetrahydrofuran (THF). 360  $\mu$ l (0.0035 moles) of triethylamine were added with stirring. After 10 minutes, 340  $\mu$ l (0.0031 moles) ethyl chloroformate were added. After stirring 10 minutes, 10 ml (0.01 moles) of 1 M KOH containing 400 mg (0.0044 moles) of  $\beta$  alanine were added to the THF solution. This mixture was stirred 60 minutes at room temperature.

50      The organic solvent was flashed off and the reaction mixture was checked by silica TLC for product. Benzene/methanol/88% formic acid (8.5/1.5/0.13) was used to develop the chromatogram.

After checking for product, the solution was adjusted to pH 7.5-8.0 and placed on a reverse phase (C-18 silica) column 2.5 x 30 cm. The reaction mixture was resolved using a linear gradient of 40-80% methanol in 0.01 M KPO<sub>4</sub> buffer pH 6.85 (1 l total volume).

55      The column effluent was collected via fraction collector and the tube contents were pooled according to individual components. The order of elution was di- $\beta$ -alanyl mesoporphyrin IX, mono- $\beta$ -alanyl mesoporphyrin IX, and unsubstituted mesoporphyrin IX.

The methanol was flashed off and the material was precipitated at pH 2.5-3.0. The ppt. was washed 3

times with dilute acetic acid in water. The product was dried under vacuum. The yield for mono- $\beta$ -alanyl mesoporphyrin IX was 23 mg.

#### EXAMPLE 12

5

##### Mono $\epsilon$ amino-n-caproyl mesoporphyrin IX (mixed anhydride method,

400mg (0.0007 moles) of mesoporphyrin IX were suspended in 50 ml of tetrahydrofuran (THF). 360  $\mu$ l (0.0035 moles) of triethylamine were added with stirring. After 10 minutes, 340  $\mu$ l (0.00414 moles) of ethylchloroformate were added. After stirring 10 minutes, 10 ml (0.01 moles) of 1M KOH containing 543 mg (0.00369 moles) of  $\epsilon$ -amino-n-caproic acid were added to the THF solution. This mixture was stirred 60 minutes at room temperature.

The organic solvent was flashed off and the reaction mixture was checked by silica TLC for product. Benzene/methanol/88% formic acid (8.5/1.5/0.13) was used to develop the chromatogram.

15

After checking for product, the solution was adjusted to pH 7.5-8.0 and placed on a reverse phase (C-18 silica) column 2.5x30cm. The reaction mixture was resolved using a linear gradient of 20-70% methanol in 0.01 M KPO<sub>4</sub> buffer pH 6.85 (1 liter total volume).

20

The column effluent was collected via fraction collector and the tube contents were pooled according to individual components. The order of elution was di- $\epsilon$ -amino-n-caproyl mesoporphyrin IX, mono- $\epsilon$ -amino-n-caproyl mesoporphyrin IX, and unsubstituted mesoporphyrin IX.

The methanol was flashed off and the material was precipitated at pH 2.5-3.0. The ppt. was washed three times with dilute acetic acid in water. The product was dried under vacuum.

#### EXAMPLE 13

25

##### Mono - $\beta$ -alanyl hematoporphyrin IX (mixed anhydride method)

400 mg (0.00059 moles) of hematoporphyrin IX dihydrochloride were suspended in 50 ml of tetrahydrofuran (THF).

30

360  $\mu$ l (0.0035 moles) of triethylamine were added with stirring. After 10 minutes, 340  $\mu$ l (0.0031 moles) of ethyl chloroformate were added. After stirring 10 minutes, 10 ml (0.01 moles) of 1M KOH containing 400 mg (0.0044 moles) of  $\beta$ -alanine were added to the THF solution. This mixture was stirred 60 minutes at room temperature.

35

The organic solvent was removed by flash evaporation, keeping the temperature below 50°C. The reaction mixture was checked for product by silica TLC using Benzene/methanol 88% formic acid (8.5/1.5/0.13) as solvent to develop the chromatogram.

40

The solution was adjusted to pH 7.5-8.0 with HCl and placed on reverse phase (C-18 silica) column 2.5 x 30 cm. The mixture was resolved using a linear gradient of 40-80% methanol in 0.01 M KPO<sub>4</sub> buffer pH 6.65 (1 liter total volume). The individual components were collected as they came off the column in the order di- $\beta$  alanyl hematoporphyrin IX, mono - $\beta$ - alanyl hematoporphyrin IX and hematoporphyrin IX.

The methanol was removed from each component by flash evaporation and the material was precipitated by adjusting the pH to 2.5 -3.0 using HCl. The precipitate was washed three times with dilute acetic acid in water at the centrifuge and the products dried under vacuum. The yield of di- $\beta$ - alanyl hematoporphyrin IX was 52mg and of mono -  $\beta$ -alanyl hematoporphyrin was 30 mg.

45

#### EXAMPLE 14

##### Mono glycyl chlorin e<sub>6</sub> (Mixed Anhydride Method)

50

625 mg of chlorin e<sub>6</sub> were dissolved in 300 ml of dimethyl formamide (DMF) and 277  $\mu$ l (0.002 mol) of triethylamine (TEA) were added to the DMF solution. After stirring for five minutes, 201  $\mu$ l (0.002 moles) of ethylchloroformate (EC) were added and stirred for 1 1/2 hours at room temperature.

75 mg (.0009 moles) of glycine (ammonia free) were added to the DMF solution and allowed to stir three hours at 50-60 °C.

55

The DMF solution was tested for product by reverse phase (C-18 silica) TLC using methanol/0.01M sodium phosphate buffer, pH 6.85, 70/30, to develop the chromatogram.

The DMF solution was flashed to near dryness, then dissolved in dilute NaOH and the pH adjusted to 2.5-3 to precipitate the solid. The precipitate was then placed on a reverse phase (C-18 silica) column 3.7

cm x 45 cm.

Fractions were eluted, using 20-40% methanol in 0.01 M sodium phosphate buffer, pH 6.85. The fractions were pooled according to individual components.

The methanol was flashed off and the material was precipitated at pH 2.5-3.0. The precipitate was washed and centrifuged 3 times in dilute acetic acid in water. The product was dried under vacuum. The yield of mono glycyl chlorin e<sub>6</sub> was 87.5 mg.

#### EXAMPLE XV

##### 10 Preparation of mono-L-serinyl chlorin e<sub>6</sub>

Chlorin e<sub>6</sub> was prepared according to the procedure of Fischer and Stern, Die Chemie Des Pyrroles, Volume II, second half, Leipzig 1940, Akademische Verlagsgesellschaft, pp. 91-93.

15 100 mg of the chlorin e<sub>6</sub> (free acid form) and 35 mg of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride were dissolved in 2 ml of N, N'-dimethylformamide. After 5 minutes, 125 mg of L-serin benzyl ester hydrochloride was added, stirred vigorously until solution was complete, then allowed to stand at room temperature for 2 hours. At this time 0.5 ml of glacial acetic acid were added, then 30 ml of methanol and 12 ml of H<sub>2</sub>O.

20 The solution was applied to a C-18 reverse phase column (14 x 2 cm). The column was washed with H<sub>2</sub>O (100 ml) then 4 ml of 1M NH<sub>4</sub>OH, then with H<sub>2</sub>O again (50 ml). Eluted product with MeOH/H<sub>2</sub>O. Fractions eluted from the column with 30% to 80% MeOH contained product as well as carbodiimid activated chlorin as determined by TLC on C-18 reverse phase plates with solvent 70% MeOH/30% buffer (0.1M sodium phosphate pH 6.85) V/V.

25 These fractions were pooled and enough 3 N NaOH was added to make the solution 0.1N in NaOH. After 1 hour, the hydrolysis was complete as determined by TLC in the above system. Removed the methanol by rotary evaporation and adjusted the pH of the solution to 7.5 with HCl. The chlorin solution was then reapplied to the same reverse phase column, washed with water, and eluted with MeOH/water using a stepwise gradient from 10 to 50% methanol. The fractions containing pure mono-L-serinyl chlorin as determined by TLC (R<sub>f</sub> slightly greater than the unsubstituted chlorin) were pooled, the methanol removed 30 by rotary evaporation, and the product dried as the trisodium salt by lyophilization.

#### EXAMPLE XVI

##### Preparation of mono-L-asparaginyl chlorin e<sub>6</sub>

35 500 mg of chlorin e<sub>6</sub> and 175 mg of 1-ethyl-3-(3-dimethylamine-propyl) carbodiimide hydrochloride were dissolved in 10 ml of N, N'-dimethyl formamide. After 5 minutes, 410 mg of L-asparagine were added. The solution was agitated for 4 hours. The asparagine did not dissolve totally during this reaction, but reverse phase (C-18) TLC 70/30 MeOH/0.01M sodium phosphate buffer pH 6.85 showed some product at 40 this time, (R<sub>f</sub> slightly greater than chlorin e<sub>6</sub>). The reaction was terminated by adding 2.5 ml glacial acetic acid, then diluting to a total volume of 100 ml with methanol, then adding 25 ml of H<sub>2</sub>O slowly, with stirring. The solution was then applied to a 14 x 2 cm reverse phase (C-18) column, washed with water then with 5 ml of 0.1M NaOH, finally with 50 ml of 0.01 M sodium phosphate buffer, pH 6.85. The product was eluted off with MeOH/H<sub>2</sub>O in a stepwise gradient from 20% MeOH to 50% MeOH. The fractions containing pure 45 mono-L-asparaginyl chlorin e<sub>6</sub>, as determined by TLC using the conditions stated above, were pooled, and the methanol removed by rotary evaporation. The product was isolated as the trisodium salt by lyophilization.

#### EXAMPLE XVII

##### 50 Preparation of mono-L-cysteinyl chlorin e<sub>6</sub>

300 mg of chlorin e<sub>6</sub> and 105 mg of 1-ethyl-3-(3-dimethylamine-propyl)carbodiimide hydrochloride were dissolved in 6 ml of N, N'-dimethylformamide. After 5 minutes, 255 mg of L-cysteine hydrochloride were 55 added. The solution was stirred at room temperature for 5 hours. The rest of the procedure is the same as for the preparation of mono-L-asparaginyl chlorin e<sub>6</sub>.

#### EXAMPLE XVIII

Preparation of mono-L-serinyl-2-formylchlorin e<sub>6</sub> (mono-L-serinyl 2-desvinyl-2-formyl-chlorin e<sub>6</sub>)

500 mg of chlorin e<sub>6</sub> trimethyl ester were prepared according to the procedure of Fischer and Stern, in Die Chemie Des Pyrroles, Volume II, second half, Leipzig 1940, Akademische Verlagsgesellschaft, pp. 98-102. The chlorin e<sub>6</sub> trimethyl ester was dissolved in 600 ml of refluxing acetone. 400 mg of Potassium permanganate and 800 mg of magnesium sulfate dissolved in 130 ml of H<sub>2</sub>O were added slowly over approximately a one hour period to the refluxing acetone solution. The solution was allowed to reflux for 1/2 hour after addition was complete. After cooling, 300 ml of methylene chloride were added, and the mixture was washed 3 times with water in a separatory funnel. The volume of methylene chloride was reduced and the product chromatographed on silica gel, eluting with a gradually increasing percentage of ethyl acetate in the CH<sub>2</sub>Cl<sub>2</sub>. The first major brown band which eluted was collected as the product, 2-Desvinyl-2-Formyl-Chlorin e<sub>6</sub>. Yield 94 mg.

The product was saponified by dissolution in refluxing n-propanol (0.1 ml/mg) and addition of 6 fold equivalent of 1N KOH. The tripotassium salt was filtered off, washed with n-propanol and dried under vacuum, forming 2-formyl chlorin e<sub>6</sub>.

100 mg of the 2-formyl chlorin e<sub>6</sub> free acid form) and 35 mg of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride were dissolved in 2 ml of N, N'-dimethyl formamide. After 5 minutes, 125 mg of L-serine benzyl ester hydrochloride was added, stirred vigorously until solution was complete, then allowed to stand at room temperature for 2 hours. At this time 0.5 ml of glacial acetic acid was added, then 30 ml of methanol and 12 ml of H<sub>2</sub>O.

The solution was applied to a C-18 reverse phase column (14 x 2 cm). The column was washed with H<sub>2</sub>O (100 ml) then 4 ml of 1M NH<sub>4</sub>OH, then with H<sub>2</sub>O again (50 ml). Eluted product with MeOH/H<sub>2</sub>O. Fractions eluted from the column with 30% to 80% MeOH contained product as well as carbodiimid activated chlorin as determined by TLC on C-18 reverse phase plates with solvent 70% MeOH/30% buffer (0.1M sodium phosphate pH 6.85) V/V.

These fractions were pooled and enough 3 N NaOH was added to make the solution 0.1N in NaOH. After 1 hour, the hydrolysis was complete as determined by TLC in the above system. Removed the methanol by rotary evaporation and adjusted the pH of the solution to 7.5 with HCl. The chlorin solution was then reapplied to the same reverse phase column, washed with water, and eluted with MeOH/water using a stepwise gradient from 10 to 50% methanol. The fractions containing pure mono-L-serinyl chlorin as determined by TLC (R<sub>f</sub> slightly greater than the unsubstituted chlorin) were pooled, the methanol removed by rotary evaporation, and the product dried as the trisodium salt by lyophilization.

EXAMPLE XIX

35

Preparation of mono-L-serinyl-deuterochlorin e<sub>6</sub> (Mono-L-Serinyl 2-desvinyl-chlorin e<sub>6</sub>)A. Deuterochlorin e<sub>6</sub>

40 Deuterochlorin e<sub>6</sub> trimethyl ester was prepared according to the procedure in Fischer and Stern in Die Chemie Des Pyrroles, Volume II, second half, Leipzig 1940, Akademische Verlagsgesellschaft, p. 104. The trimethyl ester was then hydrolyzed to the free acid state by dissolution in refluxing n-propanol (0.1 ml/mg) and adding 6 fold equivalent amounts of 1N KOH. The product was collected by filtration, after cooling, as the potassium salt and dried under vacuum.

45

B. Mono-L-Serinyl Deuterochlorin e<sub>6</sub>

100 mg of the deuterochlorin e<sub>6</sub> (free acid form) and 35 mg of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride were dissolved in 2 ml of N, N'-dimethyl formamide. After 5 minutes, 125 mg of L-serine benzyl ester hydrochloride were added, stirred vigorously until solution was complete, then allowed to stand at room temperature for 2 hours. At this time 0.5 ml of glacial acetic acid were added, then 30 ml of methanol and 12 ml of H<sub>2</sub>O.

The solution was applied to a C-18 reverse phase column (14 x 2 cm). The column was washed with H<sub>2</sub>O (100 ml) then 4 ml of 1M NH<sub>4</sub>OH, then with H<sub>2</sub>O again (50 ml). Eluted product with MeOH/H<sub>2</sub>O. Fractions eluted from the column with 30% to 80% MeOH contained product as well as carbodiimide activated chlorin as determined by TLC on C-18 reverse phase plates with solvent 70% MeOH/30% buffer (0.1M sodium phosphate pH 6.85) V/V.

The fractions were pooled and enough 3 N NaOH was added to make the solution 0.1N in NaOH.

After 1 hour, the hydrolysis was complete as determined by TLC in the above system. Removed the methanol by rotary evaporation and adjusted the pH of the solution to 7.5 with HCl. The chlorin solution was then reapplied to the same reverse phase column, washed with water, and eluted with MeOH/water using a stepwise gradient from 10 to 50% methanol. The fractions containing pure mono-L-serinyl chlorin, as determined by TLC ( $R_f$  slightly greater than the unsubstituted chlorin) were pooled, the methanol removed by rotary evaporation, and the product dried as the trisodium salt by lyophilization.

#### EXAMPLE XX

##### 10 Preparation of mono-L-serinyl-2-acetyl-chlorin e<sub>6</sub> (Mono-L-serinyl-2-desvinyl-2-acetyl chlorin e<sub>6</sub>)

###### A. 2-acetyl chlorin e<sub>6</sub>

2-acetyl chlorin e<sub>6</sub> trimethyl ester was prepared according to the procedure of Fischer and Stern, *Die Chemie Des Pyrroles*, Volume II, second half, Leipzig 1940, Akademische Verlagsgesellschaft, p. 185. The trimethyl ester was then hydrolyzed to the free acid state by dissolution in refluxing n-propanol (0.1 ml/mg) and adding 6 fold equivalent amounts of 1N KOH. The product was collected by filtration, after cooling, as the potassium salt and dried under vacuum.

###### 20 B. L-serinyl-2-acetyl chlorin e<sub>6</sub>

100 mg of the 2-acetyl chlorin e<sub>6</sub> (free acid form) and 35 mg of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride were dissolved in 2 ml of N, N'-dimethyl formamide. After 5 minutes, 125 mg of L-serine benzyl ester hydrochloride were added, stirred vigorously until solution was complete, then allowed to stand at room temperature for 2 hours. At this time 0.5 ml of glacial acetic acid were added, then 30 ml of methanol and 12 ml of H<sub>2</sub>O.

The solution was applied to a C-18 reverse phase column (14 x 2 cm). The column was washed with H<sub>2</sub>O (100 ml) then 4 ml of 1M NH<sub>4</sub>OH, then with H<sub>2</sub>O again (50 ml). Eluted product with MeOH/H<sub>2</sub>O. Fractions eluted from the column with 30% to 80% MeOH contained product as well as carbodiimide activated chlorin as determined by TLC on C-18 reverse plates with solvent 70% MeOH/30% buffer (.01M sodium phosphate, pH 6.85) V/V.

These fractions were pooled and enough 3N NaOH was added to make the solution 0.1N in NaOH. After 1 hour, the hydrolysis was complete as determined by TLC in the above system. Removed the methanol by rotary evaporation and adjusted the pH of the solution to 7.5 with HCl. The chlorin solution was then reapplied to the same reverse phase column, washed with water, and eluted with MeOH/water using a stepwise gradient from 10 to 50% methanol. The fractions containing pure mono-L-serinyl chlorin as determined by TLC ( $R_f$  slightly greater than the unsubstituted chlorin) were pooled, the methanol removed by rotary evaporation, and the product dried as the trisodium salt by lyophilization.

#### 40 EXAMPLE XXI

##### Preparation of mono-L-serinyl mesochlorin e<sub>6</sub>

###### A. Mesochlorin e<sub>6</sub>

Mesochlorin e<sub>6</sub> trimethyl ester was prepared according to the procedure of Fischer and Stern, *Die Chemie Des Pyrroles*, Volume II, second half, Leipzig 1940, Akademische Verlagsgesellschaft p. 102.

The mesochlorin e<sub>6</sub> trimethyl ester was then hydrolyzed to the free acid state by dissolution in refluxing n-propanol (0.1 ml/mg) and adding 6 fold equivalent amounts of 1N KOH. The product was collected by filtration, after cooling, as the potassium salt and dried under vacuum.

###### B. Mono-L-Serinyl Mesochlorin e<sub>6</sub>

100 mg of the mesochlorin e<sub>6</sub> (free acid form) and 35 mg of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride were dissolved in 2 ml of N, N'-dimethyl formamide. After 5 minutes, 125 mg of L-serine benzyl ester hydrochloride were added, stirred vigorously until solution was complete, then allowed to stand at room temperature for 2 hours. At this time 0.5 ml of glacial acetic acid were added, then 30 ml of methanol and 12 ml of H<sub>2</sub>O.

The solution was applied to a C-18 reverse phase column (14 x 2 cm). The column was washed with H<sub>2</sub>O (100 ml) then 4 ml of 1M NH<sub>4</sub>OH, then with H<sub>2</sub>O again (50 ml). Eluted product with MeOH/H<sub>2</sub>O. Fractions eluted from the column with 30% to 80% MeOH contained product as well as carbodiimide activated chlorin as determined by TLC on C-18 reverse phase plates with solvent 70% MeOH/30% buffer (.01M sodium phosphate pH 6.85) V/V.

These fractions were pooled and enough 3 N NaOH was added to make the solution 0.1N in NaOH. After 1 hour, the hydrolysis was complete as determined by TLC in the above system. Removed the methanol by rotary evaporation and adjusted the pH of the solution to 7.5 with HCl. The chlorin solution was then reapplied to the same reverse phase column, washed with water, and eluted with MeOH/water using a stepwise gradient from 10 to 50% methanol. The fractions containing pure mono-L-serinyl chlorin was determined by TLC ( $R_f$  slightly greater than the unsubstituted chlorin) were pooled, the methanol removed by rotary evaporation, and the product dried as the trisodium salt by lyophilization.

Utilizing the aforementioned carbodiimide or the mixed anhydride methods of Examples 8-21 the following preferred monoamide compounds of this invention are synthesized:

15

### Chlorin Derivatives

- (DL)-Serinyl-trans-mesochlorin IX
- Glycyl-trans-mesochlorin IX
- 20  $\alpha$ -(DL)-Alanyl-trans-mesochlorin IX
- $\beta$ -Alanyl-trans-mesochlorin IX
- $\epsilon$ -Amino-n-caproyl-mesochlorin IX
- (D,L)-Serinyl chlorin e<sub>6</sub>
- (D,L)-Serinyl mesochlorin e<sub>6</sub>
- 25 Glycyl chlorin e<sub>6</sub>
- Glycyl mesochlorin e<sub>6</sub>
- $\alpha$ -[D,L]-Alanyl chlorin e<sub>6</sub>
- $\alpha$ -(D,L) Alanyl mesochlorin e<sub>6</sub>
- $\beta$ -Alanyl chlorin e<sub>6</sub>
- 30  $\beta$ -Alanyl mesochlorin e<sub>6</sub>
- $\epsilon$ -Amino-n-caproyl chlorin e<sub>6</sub>
- $\epsilon$ -Amino-n-caproyl mesochlorin e<sub>6</sub>
- (D,L)-Serinyl chlorin e<sub>4</sub>
- (D,L)-Serinyl mesochlorin e<sub>4</sub>
- 35 (D,L)-Serinyl isochlorin e<sub>4</sub>
- (D,L)-Serinyl mesoischlorin e<sub>4</sub>
- Glycyl chlorin e<sub>4</sub>
- Glycyl mesochlorin e<sub>4</sub>
- Glycyl isochlorin e<sub>4</sub>
- 40 Glycyl mesoischlorin e<sub>4</sub>
- $\alpha$ -(DL)-Alanyl chlorin e<sub>4</sub>
- $\alpha$ -(DL)-Alanyl mesochlorin e<sub>4</sub>
- $\alpha$ -(DL)-Alanyl isochlorin e<sub>4</sub>
- $\alpha$ -(DL)-Alanyl mesoischlorin e<sub>4</sub>
- 45  $\beta$ -Alanyl chlorin e<sub>4</sub>
- $\beta$ -Alanyl mesochlorin e<sub>4</sub>
- $\beta$ -Alanyl isochlorin e<sub>4</sub>
- $\beta$ -Alanyl mesoischlorin e<sub>4</sub>
- $\epsilon$ -Amino-n-caproyl chlorin e<sub>4</sub>
- 50  $\epsilon$ -Amino-n-caproyl mesochlorin e<sub>4</sub>
- $\epsilon$ -Amino-n-caproyl isochlorin e<sub>4</sub>
- $\epsilon$ -Amino-n-caproyl mesoischlorin e<sub>4</sub>
- (D,L)-Serinylphotoporphyrin IX
- Glycylphotoporphyrin IX
- 55  $\alpha$ -(D,L)-Alanylphotoporphyrin IX
- $\beta$ -Alanylphotoporphyrin IX
- $\epsilon$ -Amino-n-caproylphotoporphyrin IX
- Threoninyl chlorin e<sub>5</sub>

- Tyrosyl chlorin e<sub>6</sub>  
 Valyl chlorin e<sub>6</sub>  
 Leucyl chlorin e<sub>6</sub>  
 Isoleucyl chlorin e<sub>6</sub>
- 5 Prolyl chlorin e<sub>6</sub>  
 Methionyl chlorin e<sub>6</sub>  
 Histidyl chlorin e<sub>6</sub>  
 Arginyl chlorin e<sub>6</sub>  
 Lysyl chlorin e<sub>6</sub>
- 10 Glutaminyl chlorin e<sub>6</sub>  
 4-hydroxyprolyl chlorin e<sub>6</sub>  
 5-hydroxylysyl chlorin e<sub>6</sub>  
 ε-amino-n-caproyl chlorin e<sub>6</sub>  
 γ-aminobutanoyl chlorin e<sub>6</sub>
- 15 3-methyl histidyl chlorin e<sub>6</sub>  
 Alanyl 2-acetyl-chlorin e<sub>6</sub>  
 Valyl 2-acetyl-chlorin e<sub>6</sub>  
 Leucyl 2-acetyl-chlorin e<sub>6</sub>  
 Isoleucyl 2-acetyl-chlorin e<sub>6</sub>
- 20 Prolyl 2-acetyl-chlorin e<sub>6</sub>  
 Methionyl 2-acetyl-chlorin e<sub>6</sub>  
 Glycyl 2-acetyl-chlorin e<sub>6</sub>  
 Serinyl 2-acetyl-chlorin e<sub>6</sub>  
 Threoninyl 2-acetyl-chlorin e<sub>6</sub>
- 25 Cysteinyl 2-acetyl-chlorin e<sub>6</sub>  
 Tyrosyl 2-acetyl-chlorin e<sub>6</sub>  
 Asparginyl 2-acetyl-chlorin e<sub>6</sub>  
 Lysyl 2-acetyl-chlorin e<sub>6</sub>  
 Arginyl 2-acetyl-chlorin e<sub>6</sub>
- 30 Histidyl 2-acetyl-chlorin e<sub>6</sub>  
 Glutaminyl 2-acetyl-chlorin e<sub>6</sub>  
 4-hydroxy-prolyl 2-acetyl-chlorin e<sub>6</sub>  
 5-hydroxy lysyl 2-acetyl-chlorin e<sub>6</sub>  
 ε-amino-n-caproyl 2-acetyl-chlorin e<sub>6</sub>
- 35 γ-aminobutanoyl 2-acetyl-chlorin e<sub>6</sub>  
 3-methyl histidyl 2-acetyl-chlorin e<sub>6</sub>  
 β-alanyl 2-acetyl-chlorin e<sub>6</sub>  
 Alanyl 2 formyl chlorin e<sub>6</sub>  
 Valyl 2 formyl chlorin e<sub>6</sub>
- 40 Leucyl 2 formyl chlorin e<sub>6</sub>  
 Isoleucyl 2 formyl chlorin e<sub>6</sub>  
 Prolyl 2 formyl chlorin e<sub>6</sub>  
 Methionyl 2 formyl chlorin e<sub>6</sub>  
 Glycyl 2 formyl chlorin e<sub>6</sub>
- 45 Serinyl 2 formyl chlorin e<sub>6</sub>  
 Threoninyl 2 formyl chlorin e<sub>6</sub>  
 Cysteinyl 2 formyl chlorin e<sub>6</sub>  
 Tyrosyl 2 formyl chlorin e<sub>6</sub>  
 Asparginyl 2 formyl chlorin e<sub>6</sub>
- 50 Lysyl 2 formyl chlorin e<sub>6</sub>  
 Arginyl 2 formyl chlorin e<sub>6</sub>  
 Histidyl 2 formyl chlorin e<sub>6</sub>  
 Glutaminyl 2 formyl chlorin e<sub>6</sub>  
 4-hydroxy-prolyl 2 formyl chlorin e<sub>6</sub>
- 55 5-hydroxy lysyl 2 formyl chlorin e<sub>6</sub>  
 ε-amino-n-caproyl 2 formyl chlorin e<sub>6</sub>  
 γ-aminobutanoyl 2 formyl chlorin e<sub>6</sub>  
 3-methyl histidyl 2 formyl chlorin e<sub>6</sub>

- $\beta$ -alanyl 2 formyl chlorin e<sub>6</sub>  
Alanyl Deuterochlorin e<sub>6</sub>  
Valyl Deuterochlorin e<sub>6</sub>  
Leucyl D uterochlorin e<sub>6</sub>  
5   Isoleucyl Deuterochlorin e<sub>6</sub>  
Prolyl Deuterochlorin e<sub>6</sub>  
Methionyl Deuterochlorin e<sub>6</sub>  
Glycyl Deuterochlorin e<sub>6</sub>  
Serinyl Deuterochlorin e<sub>6</sub>  
10   Threoninyl Deuterochlorin e<sub>6</sub>  
Cysteinyl Deuterochlorin e<sub>6</sub>  
Tyrosyl Deuterochlorin e<sub>6</sub>  
Asparginyl Deuterochlorin e<sub>6</sub>  
Lysyl Deuterochlorin e<sub>6</sub>  
15   Arginyl Deuterochlorin e<sub>6</sub>  
Histidyl Deuterochlorin e<sub>6</sub>  
Glutaminyl Deuterochlorin e<sub>6</sub>  
4-hydroxy-prolyl Deuterochlorin e<sub>6</sub>  
5-hydroxy lysyl Deuterochlorin e<sub>6</sub>  
20    $\epsilon$ -amino-n-caproyl Deuterochlorin e<sub>6</sub>  
 $\gamma$ -aminobutanoyl Deuterochlorin e<sub>6</sub>  
3-methyl histidyl Deuterochlorin e<sub>6</sub>  
 $\beta$ -alanyl Deuterochlorin e<sub>6</sub>  
valyl mesochlorin e<sub>6</sub>  
25   Leucyl mesochlorin e<sub>6</sub>  
Isoleucyl mesochlorin e<sub>6</sub>  
Prolyl mesochlorin e<sub>6</sub>  
Methionyl mesochlorin e<sub>6</sub>  
Serinyl mesochlorin e<sub>6</sub>  
30   Threoninyl mesochlorin e<sub>6</sub>  
Cysteinyl mesochlorin e<sub>6</sub>  
Tyrosyl mesochlorin e<sub>6</sub>  
Asparginyl mesochlorin e<sub>6</sub>  
Lysyl mesochlorin e<sub>6</sub>  
35   Arginyl mesochlorin e<sub>6</sub>  
Histidyl mesochlorin e<sub>6</sub>  
Glutaminyl mesochlorin e<sub>6</sub>  
4-hydroxy-prolyl mesochlorin e<sub>6</sub>  
5-hydroxy lysyl mesochlorin e<sub>6</sub>  
40    $\gamma$ -aminobutanoyl mesochlorin e<sub>6</sub>  
3-methyl histidyl mesochlorin e<sub>6</sub>

Porphyrin Derivatives

- 45   (D,L)-Serinylmesoporphyrin IX  
Glycylmesoporphyrin IX  
 $\alpha$ -(DL)-Alanylmesoporphyrin IX  
 $\beta$ -Alanylmesoporphyrin IX  
 $\epsilon$ -Amino-n-caproylmesoporphyrin IX  
50   (D,L)-Serinylprotoporphyrin IX  
Glycylprotoporphyrin IX  
 $\alpha$ -(D,L)-Alanylprotoporphyrin IX  
 $\beta$ -Alanylprotoporphyrin IX  
 $\epsilon$ -Amino-n-caproylprotoporphyrin IX  
55   (D,L)-Serinyldeuteroporphyrin IX  
Glycyldeuteroporphyrin IX  
 $\alpha$ -(D,L)-Alanyldeuteroporphyrin IX  
 $\beta$ -Alanyldeuteroporphyrin IX

- ε-Amino-n-caproyldeuteroporphyrin IX  
 tetra- (D,L)-Serinylcoproporphyrin III  
 tetra- Glycylcoproporphyrin III  
 tetra- α-(D,L)-Alanylcoproporphyrin III  
 5 tetra- β-Alanylcoproporphyrin III  
 tetra- ε-Amino-n-caproylcoproporphyrin III  
 (D,L)-Serinylhematoporphyrin IX  
 Glycylhematoporphyrin IX  
 α-(D,L)-Alanylhematoporphyrin IX  
 10 β-Alanylhematoporphyrin IX  
 ε-Amino-n-caproylhematoporphyrin IX

#### Bacteriochlorin Derivatives

- 15 (D,L)-Serinylbacteriochlorin e<sub>4</sub>  
 Glycylbacteriochlorin e<sub>4</sub>  
 α-(DL)-Alanylbacteriochlorin e<sub>4</sub>  
 β-Alanylbacteriochlorin e<sub>4</sub>  
 ε-Amino-n-caproylbacteriochlorin e<sub>4</sub>  
 20 (D,L)-Serinylbacterioisochlorin e<sub>4</sub>  
 Glycylbacterioisochlorin e<sub>4</sub>  
 α-(DL)-Alanylbacterioisochlorin e<sub>4</sub>  
 β-Alanylbacterioisochlorin e<sub>4</sub>  
 ε-Amino-n-caproylbacterioisochlorin e<sub>4</sub>  
 25 (D,L)-Serinylbacteriochlorin e<sub>6</sub>  
 Glycylbacteriochlorin e<sub>6</sub>  
 α-(DL)-Alanylbacteriochlorin e<sub>6</sub>  
 β-Alanylbacteriochlorin e<sub>6</sub>  
 ε-Amino-n-caproylbacteriochlorin e<sub>6</sub>

30 Other amino acid derivatives of the tetrapyrroles can also be prepared. The following amino acids can also be used to prepare the mono-, di-, tri-, or where appropriate, the tetra-amino acid derivatives of the chlorins, porphyrins, or bacteriochlorins, employing the procedures of one of the aforementioned methods: piperidine-2-carboxylic acid, piperidine-6-carboxylic acid, pyrrole-2-carboxylic acid, pyrrole-5-carboxylic acid, piperidine-6-propionic acid, and pyrrole-5-acetic acid

35 Mixed amino acid derivatives of the tetrapyrroles can also be prepared. The various chlorin derivatives, porphyrin derivatives and bacteriochlorin derivatives can include any two or three of the following amino acids: glycine, serine, threonine, cysteine, tyrosine, asparagine, glutamine, lysine, arginine, histidine, α-alanine, β-alanine, valine, leucine, isoleucine, proline, α-phenylalanine, β-phenylalanine, tryptophan, methionine, ε-amino-n-caproic acid, piperidine-2-carboxylic acid, pyrrole-5-carboxylic acid, piperidine-6-propionic acid, pyrrole-5-acetic acid.

40 Physical characteristics of the compounds (relative polarity) is measured by a standard chromatographic system. The chromatographic data (Rf values) were measured on Baker silica gel-C18 thin layer chromatographic plates, the particle size of which is 20 μM, and the coating thickness of which is 200 μM. The solvent system for these chromatographic runs consisted of 75% methanol, and 25% 0.01 M potassium phosphate buffer, pH 6.85. The compounds were spotted and dried on the plate as the sodium salts, at approximately neutral pH and minimum salt concentrations. The Rf values for the various derivatives are tabulated in TABLE 1. Spectroscopic data are indicated in TABLE 2.

TABLE 1

Rf VALUES			
	Compounds	Derivative	Rf
5	Mesoporphyrin IX	--	.32
	Mesoporphyrin IX	mono- $\alpha$ -alanyl	.44
10	Mesoporphyrin IX	mono- $\beta$ -alanyl	.44
	Mesoporphyrin IX	di- $\alpha$ -alanyl	.51
	Mesoporphyrin IX	di- $\beta$ -alanyl	.49
	Mesoporphyrin IX	mono-glycycl	.47
15	Mesoporphyrin IX	di-seryl	.58
	Mesoporphyrin IX	di-glycycl	.54
	Mesoporphyrin IX	di- $\epsilon$ -aminocaproyl	.34
	Hematoporphyrin IX	--	.78
	Hematoporphyrin IX	mono- $\beta$ -alanyl	.83
	Hematoporphyrin IX	di- $\beta$ -alanyl	.83
20	Chlorin e <sub>6</sub>	--	.66
	Chlorin e <sub>6</sub>	di-L- $\alpha$ -serinyl	.78
	2-formyl chlorin e <sub>6</sub>	-----	0.74
	2-acetyl chlorin e <sub>6</sub>	-----	0.71
	Deutero chlorin e <sub>6</sub>	-----	0.79
25	Mesochlorin e <sub>6</sub>	-----	0.69
	2-formyl chlorin e <sub>6</sub>	Mono-L-serinyl	0.87
	2-acetyl chlorin e <sub>6</sub>	Mono-L-serinyl	0.86
	Deuterochlorin e <sub>6</sub>	Mono-L-serinyl	0.90
	Mesochlorin e <sub>6</sub>	Mono-L-serinyl	0.73
30	Chlorin e <sub>6</sub>	Mono-L-asparaginyl	0.72
	Chlorin e <sub>6</sub>	Mono-L-cysteinyl	0.93
	Chlorin e <sub>6</sub>	Mono-L-serinyl	0.72

35

40

45

50

55

TABLE II  
Spectroscopic Absorption Data

Solvent: in all cases is p-di xane.

5	Compounds	Absorption Maxima (nm) in Visible Region	mM Extinction Coefficient (EmM) ± 10%	Soret Band nm
10	Phytocryptoporphyrin IX isomer mixture	668	38	415
15	Phaeophorbide <u>a</u>	667	35	408.6
20	Pyropheophorbide <u>a</u>	668	38	411.2
25	Trans-mesochlorin IX	643	60	388
30	Chlorin <u>e</u> <sub>6</sub>	665.6	42	402
35	Hematoxyporphyrin derivative (HPD)	626	2.9	399
40	Mesochlorin <u>e</u> <sub>6</sub>	651		399
45	2-acetyl-chlorin <u>e</u> <sub>6</sub>	712,683		410
50	2-formyl-chlorin <u>e</u> <sub>6</sub>	627		412
55	Deuterochlorin <u>e</u> <sub>6</sub>	653		398
60	Chlorin <u>e</u> <sub>6</sub>	666		402

Absorption data for the amino acid conjugates is identical to the parent chlorins.

The following protocol describes the procedure for the utilization of these new compounds of the present invention in the treatment of rat tumors.

#### EXAMPLE XXII

The photodynamic therapy experiments have been carried out on Buffalo rats, using the transplantable tumor, Morris Hepatoma 7777. The tumors were transplanted subcutaneously on the outside of the thigh. During treatment, the tumors ranges in size between 1 and 2.5 cm in diameter.

The general treatment regime is as follows. The rats are injected with a solution of the chlorin prepared as follows: 20 mg of the sodium salt of the chlorin was dissolved in 1 ml of 0.9% NaCl. The chlorin solution was then injected intravenously through the external jugular while the rat was anesthetized with ether. The volume of solution injected was calculated based upon the weight of the animal and the dosage, on a weight to weight basis, for the particular experiment. A specified time interval was then allowed to elapse before light treatment was instigated.

Light treatment of the rats was without anesthesia. The rats were restrained, the hair removed in the treatment area and treated with laser light from a Cooper Aurora argon pumped, tunable dye laser.

The laser was equipped with a fiber optic light delivery system coupled to a microlens system developed by Dr. Daniel Doiron, D.R.D. Consulting, Santa Barbara, California.

The lens disperses the laser beam, providing a circular distribution of light with homogenous light intensity throughout the area of the incident light beam. The wavelength of light was adjusted using a Hartridge reversion spectroscope. The light intensity was determined using a Yellow Springs Instrument, Model 65A, radiometer.

The micro lens was positioned at such a distance from the skin of the animal so as to provide an illumination diameter of 1.5cm, and the light flux was varied by control of the laser output.

Subsequent to illumination, the animal was returned to its cage and, 24 hours later, it was treated

intravenously in the external jugular vein with 14 mg of Evans Blue dye, dissolved in 250  $\mu$ l of 0.9% NaCl. Two hours after injection, the rat was sacrificed and the tumor cross-sectioned. The extent of tumor necrosis was assessed by the lack of dye uptake (1), and the depth of the necrotic cross section of the tumor was recorded in millimeters.

5 Table III summarizes the effects of these drugs on tumors and includes a range of wavelengths, dosages, intensities, and time intervals for treatment. This has been necessary, in order to attempt to establish the optimal conditions for phototherapy utilizing this new drug. The conditions described result in measurable and significant damage to the tumors.

10 In all cases except where noted, tissue damage occurred selectively to the tumor tissue as assayed by the Evans Blue method, even though, in nearly all cases, normal skin overlayed the tumor and the treatment area overlapped significant areas of normal muscle tissue.

15 The photodynamic therapy data is presented in tabular form. Column No. 2 is the total light dose administered in terms of Joules per square centimeter. Column No. 3 is the dose of chlorin administered in terms of mg of drug per kilogram of rat body weight. Column No. 4 is the time lapse between administration of drug and treatment with laser light. Column No. 5 is the wavelength of treatment light in nanometers. Column No. 6 is the intensity of the treatment light in milliwatts per square centimeter. In Column No. 7,  $\bar{x}$  is the mean depth of necrosis in millimeters of the tumor tissue, i.e., the distance from the necrotic top of the tumor next to the skin to the necrotic edge of the tumor most distant from the skin.

S.D. is the standard deviation of  $\bar{x}$ .

20 (N) is the number of tumors or legs involved in the experiment.

Column No. 8 is the range of depth of necrosis in millimeters within the group.

25

30

35

40

45

50

55

5

10

15

20

25

30

35

40

45

50

TABLE III

Tumor	Joules/ cm <sup>2</sup>	Drug dose mg/kg	Time in hrs btwn drugs & light	Wave lngth nm	Intensity mV/cm <sup>2</sup>	$\bar{x}$ s.d. (n)	Range mm
<u>Mono-Glycyl chlorin e<sub>6</sub></u>							
7777	20	20	24	665	100	3.9±3.0 (5)	2-9*
<u>Mono-L-<math>\alpha</math>-alanyl chlorin e<sub>6</sub></u>							
7777	20	20	24	665	100	3.8±1.8 (2)	2.5-5
<u>Mono-L-<math>\alpha</math>-serinyl chlorin e<sub>6</sub></u>							
7777	20	20	24	665	100	6.3±2.7 (6)	3-10
<u>Diglycyl chlorin e<sub>6</sub></u>							
7777	20	20	24	665	100	4.7±1.0 (3)	3.5-5.5

\* 3 of 8 tumors showed no necrosis due to drug and light.

## 55 EXAMPLE XXIII

The treatment and evaluation procedure is as follows:

DBA/2 Ha Ros-d + Ha.mic with SMT-F transplanted tumors either in the exterior part of the hind leg or

the side of the mouse were injected intravenously via the external jugular or the intraperitoneally with the photosensitizing drug. At the specified time after injection, the area over the tumor was shaved and the light treatment begun.

Light from a Copper Aurora argon pumped tunable dye laser was administered via a micro lens system (developed by Dr. Daniel Doiron, D.R.D. Consulting, Santa Barbara, California) coupled through a quartz fiber to the laser, the optical properties of the lens are such that the light exits the lens in a circular pattern with homogenous intensity throughout the lighted area. The diameter of the lighted area is a function of the distance from the lens.

The light intensity was measured with a Yellow Springs Instrument Model 65 A Radiometer at the point of treatment. A 1.5 cm diameter circle of the animal's skin, centered as closely as possible over the tumor, was irradiated in all the experiments. The intensity, wavelength, and dosage of light is included in the data for individual groups of animals. Wavelengths are adjusted, using a Hartridge reversion spectroscope to within 1 nm of the stated value.

Twenty four hours after light treatment, each mouse received 5 mg of Evans Blue Dye intravenously <sup>(1)</sup>. After an additional two hours, the mice were sacrificed and the tumors were sectioned vertically through the center of the light treated area. Unaffected tumor was stained blue as was unaffected normal tissue. Necrotic or affected areas were white or red in appearance. Measurements on both the whole tumors and affected areas of the tumors were made vertically and horizontally with calipers to the nearest one half millimeter. The results of representative compounds are depicted in the following tables:

20

25

30

35

40

45

50

55

(1) M.C. Berenbaum. Br. J. Cancer. 45:571 (1982).

TABLE IV - HOUSE DATA

	Mono-L-serinyl mes chlorin e6				
1	ANIMAL GROUP NO.	78	78	78	78
2	DATE EXPERIMENT STARTED	--	--	--	--
3	MOUSE NO.	1	2	3	4
4	SEX OF MOUSE	m	m	m	m
5	WT. OF MOUSE (gms)	23.3	25.8	21.0	22.8
10	DRUG DOSE (mg/kg)	100.0	100.0	100.0	100.0
15	METHOD OF DRUG INTRODUCTION	iv	iv	iv	iv
20	TIME BETW. DRUG INTRODUCTION + LIGHT TREATMENT (hrs)	24.0	24.0	24.0	24.0
25	TUMOR TYPE	SMT-F	SMT-F	SMT-F	SMT-F
30	POSITION OF TUMOR ON ANIMAL	r leg	r leg	r leg	r leg
35	LIGHT TREATMENT INTENSITY (mW/cm <sup>2</sup> )	200.0	200.0	200.0	200.0
40	LIGHT DOSE (J/cm <sup>2</sup> )	300.0	300.0	300.0	300.0
45	WAVE LENGTH USED TO TREAT TUMOR (nm)	651	651	651	651
50	DATE ANIMAL INJECTED WITH DRUG	--	--	--	--
55	LENGTH OF TUMOR ON INJECTION DATE (cm)	1.00	0.90	0.75	0.55
60	WIDTH OF TUMOR ON INJECTION DATE (cm)	0.60	0.55	0.65	0.45
65	DEPTH OF TUMOR ON INJECTION DATE (cm)	0.45	0.30	0.30	0.20
70	DATE ANIMAL SACRIFICED	--	--	--	--
75	LENGTH OF TUMOR ON SACRIFICE DATE (cm)	1.30	1.30	0.30	0.90
80	WIDTH OF TUMOR ON SACRIFICE DATE (cm)	1.20	1.00	0.80	0.70
85	DEPTH OF TUMOR ON SACRIFICE DATE (cm)	0.65	0.70	0.65	0.60
90	LENGTH OF EFFECT UPON TUMOR ON SACRIFICE DATE (cm)	0.00	0.80	0.10	0.60
95	WIDTH OF EFFECT UPON TUMOR ON SACRIFICE DATE (cm)	0.00	0.40	0.10	0.60
100	DEPTH OF EFFECT UPON TUMOR ON SACRIFICE DATE (cm)	0.00	0.30	0.10	0.20
105	COMMENTS AS RESULT OF TUMOR ASSESSMENT	no effect	red skin effect 0.9 x 0.9cm		red skin effect 0.6x0.6cm no effect on the tumor

50

55

TABLE V - MOUSE DATA

COMPOUND USED		Mono-L-serinyl 2-acetyl chlorin e6	
1	ANIMAL GROUP NO.	81	81
5	2 DATE EXPERIMENT STARTED	--	--
10	3 MOUSE NO.	1	2
15	4 SEX OF MOUSE	m	m
20	5 WT. OF MOUSE(gms)	26.5	21.0
25	6 DRUG DOSE(mg/kg)	100.0	100.0
30	7 METHOD OF DRUG INTRODUCTION	iv	iv
35	8 TIME BETW. DRUG INTRODUCTION + LIGHT TREATMENT(hrs)	24.0	24.0
40	9 TUMOR TYPE	SMT-F	SMT-F
45	10 POSITION OF TUMOR ON ANIMAL	r leg	r leg
50	11 LIGHT TREATMENT INTENSITY (mJ/cm <sup>2</sup> )	200.0	200.0
55	12 LIGHT DOSE(J/cm <sup>2</sup> )	300.0	300.0
60	13 WAVE LENGTH USED TO TREAT TUMOR (nm)	680	680
65	14 DATE ANIMAL INJECTED WITH DRUG	--	--
70	15 LENGTH OF TUMOR ON INJECTION DATE(cm)	0.80	0.80
75	16 WIDTH OF TUMOR ON INJECTION DATE(cm)	0.45	0.60
80	17 DEPTH OF TUMOR ON INJECTION DATE(cm)	0.40	0.40
85	18 DATE ANIMAL SACRIFICED	--	--
90	19 LENGTH OF TUMOR ON SACRIFICE DATE(cm)	1.20	0.90
95	20 WIDTH OF TUMOR ON SACRIFICE DATE(cm)	0.90	0.70
100	21 DEPTH OF TUMOR ON SACRIFICE DATE(cm)	0.60	0.40
105	22 LENGTH OF EFFECT UPON TUMOR ON SACRIFICE DATE(cm)	0.00	0.00
110	23 WIDTH OF EFFECT UPON TUMOR ON SACRIFICE DATE(cm)	0.00	0.00
115	24 DEPTH OF EFFECT UPON TUMOR ON SACRIFICE DATE(cm)	0.00	0.00
120	25 COMMENTS AS RESULT OF TUMOR ASSESSMENT	no effect	no effect

TABLE VI - MOUSE DATA

	Mono-L-serinyl deuterochlorin e6				
1	ANIMAL GROUP NO.	82	82	82	82
2	DATE EXPERIMENT STARTED	--	--	--	--
3	MOUSE NO.	1	2	3	4
4	SEX OF MOUSE	m	m	m	m
5	WT. OF MOUSE (gms)	25.7	23.2	21.3	20.5
6	DRUG DOSE (mg/kg)	100.0	100.0	100.0	100.0
7	METHOD OF DRUG INTRODUCTION	iv	iv	iv	iv
8	TIME BETW. DRUG INTRODUCTION + LIGHT TREATMENT (hrs)	24.0	24.0	24.0	24.0
9	TUMOR TYPE	SMT-F	SMT-F	SMT-F	SMT-F
10	POSITION OF TUMOR ON ANIMAL	r leg	r leg	r leg	r leg
11	LIGHT TREATMENT INTENSITY (mJ/cm <sup>2</sup> )	200.0	200.0	200.0	200.0
12	LIGHT DOSE (J/cm <sup>2</sup> )	300.0	300.0	300.0	300.0
13	WAVE LENGTH USED TO TREAT TUMOR (nm)	655	655	655	655
14	DATE ANIMAL INJECTED WITH DRUG	--	--	--	--
15	LENGTH OF TUMOR ON INJECTION DATE (cm)	1.40	1.75	1.90	1.45
16	WIDTH OF TUMOR ON INJECTION DATE (cm)	1.15	1.10	0.65	1.05
17	DEPTH OF TUMOR ON INJECTION DATE (cm)	0.75	1.00	0.20	0.90
18	DATE ANIMAL SACRIFICED	--	--	--	--
19	LENGTH OF TUMOR ON SACRIFICE DATE (cm)	1.70	1.80	2.20	1.75
20	WIDTH OF TUMOR ON SACRIFICE DATE (cm)	0.80	1.15	1.00	1.25
21	DEPTH OF TUMOR ON SACRIFICE DATE (cm)	0.60	0.60	0.80	0.50
22	LENGTH OF EFFECT UPON TUMOR ON SACRIFICE DATE (cm)	0.30	0.40	0.40	1.00
23	WIDTH OF EFFECT UPON TUMOR ON SACRIFICE DATE (cm)	0.35	0.40	0.40	1.15
24	DEPTH OF EFFECT UPON TUMOR ON SACRIFICE DATE (cm)	0.15	0.20	0.20	0.20
25	COMMENTS AS RESULT OF TUMOR ASSESSMENT				no effect

TABLE VII - MOUSE DATA

COMPOUND USED		Mono-L-asparaginyl chlorin e6				
1	ANIMAL GROUP NO.	83	83	83	83	83
5	2 DATE EXPERIMENT STARTED	--	--	--	--	--
3	3 MOUSE NO.	1	2	3	4	5
4	4 SEX OF MOUSE	m	m	m	m	m
5	5 WT. OF MOUSE (gms)	25.4	25.0	25.8	24.6	24.1
10	6 DRUG DOSE (mg/kg)	100.0	100.0	100.0	100.0	100.0
15	7 METHOD OF DRUG INTRODUCTION	iv	iv	iv	iv	iv
20	8 TIME BETW. DRUG INTRODUCTION + LIGHT TREATMENT (hrs)	24.0	24.0	24.0	24.0	24.0
25	9 TUMOR TYPE	SMT-F	SMT-F	SMT-F	SMT-F	SMT-F
30	10 POSITION OF TUMOR ON ANIMAL	r leg	r leg	r leg	r leg	r leg
35	11 LIGHT TREATMENT INTENSITY (mV/cm <sup>2</sup> )	200.0	200.0	200.0	200.0	200.0
40	12 LIGHT DOSE (J/cm <sup>2</sup> )	300.0	300.0	300.0	300.0	300.0
45	13 WAVE LENGTH USED TO TREAT TUMOR (nm)	665	665	665	665	665
50	14 DATE ANIMAL INJECTED WITH DRUG	--	--	--	--	--
55	15 LENGTH OF TUMOR ON INJECTION DATE (cm)	1.30	1.20	1.30	1.25	1.00
60	16 WIDTH OF TUMOR ON INJECTION DATE (cm)	0.90	0.90	1.05	0.75	0.70
65	17 DEPTH OF TUMOR ON INJECTION DATE (cm)	0.60	0.55	0.60	0.60	0.50
70	18 DATE ANIMAL SACRIFICED	--	--	--	--	--
75	19 LENGTH OF TUMOR ON SACRIFICE DATE (cm)	1.05	1.40	1.60	1.60	1.30
80	20 WIDTH OF TUMOR ON SACRIFICE DATE (cm)	0.90	0.85	0.80	0.75	0.90
85	21 DEPTH OF TUMOR ON SACRIFICE DATE (cm)	0.65	0.65	0.60	0.65	0.60
90	22 LENGTH OF EFFECT UPON TUMOR ON SACRIFICE DATE (cm)	1.05	1.40	1.10	1.60	1.05
95	23 WIDTH OF EFFECT UPON TUMOR ON SACRIFICE DATE (cm)	0.90	0.85	0.50	0.75	0.60
100	24 DEPTH OF EFFECT UPON TUMOR ON SACRIFICE DATE (cm)	0.50	0.60	0.35	0.65	0.45
105	25 COMMENTS AS RESULT OF TUMOR ASSESSMENT	skin effect 0.65 x 0.60cm	skin effect 0.8 x 0.9cm		skin effect 0.95 x 0.95cm; muscle damage	skin effect 0.5 x 0.5cm

TABLE VIII - MOUSE DATA

COMPOUND USED		Mono-L-serinyl-2-formyl chlorin e6			
1	ANIMAL GROUP NO.	85	85	85	85
5	2 DATE EXPERIMENT STARTED	--	--	--	--
3	3 MOUSE NO.	1	2	3	4
4	4 SEX OF MOUSE	m	m	m	m
5	5 WT. OF MOUSE(gms)	26.0	20.5	20.2	28.8
10	6 DRUG DOSE(mg/kg)	100.0	100.0	100.0	100.0
7	7 METHOD OF DRUG INTRODUCTION	iv	iv	iv	iv
8	8 TIME BETW. DRUG INTRODUCTION + LIGHT TREATMENT(hrs)	24.0	24.0	24.0	24.0
9	9 TUMOR TYPE	SMT-F	SMT-F	SMT-F	SMT-F
10	10 POSITION OF TUMOR ON ANIMAL	r leg	r leg	r leg	r leg
11	11 LIGHT TREATMENT INTENSITY (mV/cm <sup>2</sup> )	200.0	200.0	200.0	200.0
12	12 LIGHT DOSE(J/cm <sup>2</sup> )	300.0	300.0	300.0	300.0
13	13 WAVE LENGTH USED TO TREAT TUMOR (nm)	690	690	690	690
14	14 DATE ANIMAL INJECTED WITH DRUG	--	--	--	--
15	15 LENGTH OF TUMOR ON INJECTION DATE(cm)	1.60	1.70	1.80	1.60
16	16 WIDTH OF TUMOR ON INJECTION DATE(cm)	1.00	1.10	1.20	1.00
17	17 DEPTH OF TUMOR ON INJECTION DATE(cm)	0.70	0.75	0.60	0.70
18	18 DATE ANIMAL SACRIFICED	--	--	--	--
19	19 LENGTH OF TUMOR ON SACRIFICE DATE(cm)	1.60	1.60	1.00	1.70
20	20 WIDTH OF TUMOR ON SACRIFICE DATE(cm)	1.05	1.10	1.30	1.10
21	21 DEPTH OF TUMOR ON SACRIFICE DATE(cm)	0.75	0.80	0.80	0.80
22	22 LENGTH OF EFFECT UPON TUMOR ON SACRIFICE DATE(cm)	0.40	1.30	0.90	0.00
23	23 WIDTH OF EFFECT UPON TUMOR ON SACRIFICE DATE(cm)	0.30	0.60	0.80	0.00
24	24 DEPTH OF EFFECT UPON TUMOR ON SACRIFICE DATE(cm)	0.15	0.25	0.30	0.00
25	25 COMMENTS AS RESULT OF TUMOR ASSESSMENT				no effect

50

55

TABLE IX - MOUSE DATA

	Mono-L-cysteinyl chlorin e6					
1	ANIMAL GROUP NO.	86	86	86	86	
5	2 DATE EXPERIMENT STARTED	--	--	--	--	
10	3 MOUSE NO.	1	2	3	4	
15	4 SEX OF MOUSE	m	m	m	m	
20	5 WT. OF MOUSE(gms)	26.0	26.2	27.1	22.2	
25	6 DRUG DOSE(mg/kg)	100.0	100.0	100.0	100.0	
30	7 METHOD OF DRUG INTRODUCTION	iv	iv	iv	iv	
35	8 TIME BETW. DRUG INTRODUCTION + LIGHT TREATMENT (hrs)	24.0	24.0	24.0	24.0	
40	9 TUMOR TYPE	SMT-F	SMT-F	SMT-F	SMT-F	
45	10 POSITION OF TUMOR ON ANIMAL	r leg	r leg	r leg	r leg	
50	11 LIGHT TREATMENT INTENSITY (mW/cm <sup>2</sup> )	200.0	200.0	200.0	200.0	
55	12 LIGHT DOSE(J/cm <sup>2</sup> )	300.0	300.0	300.0	300.0	
60	13 WAVE LENGTH USED TO TREAT TUMOR (nm)	665	665	665	665	
65	14 DATE ANIMAL INJECTED WITH DRUG	--	--	--	--	
70	15 LENGTH OF TUMOR ON INJECTION DATE(cm)	1.45	1.60	2.05	0.90	
75	16 WIDTH OF TUMOR ON INJECTION DATE(cm)	1.00	1.20	1.60	0.85	
80	17 DEPTH OF TUMOR ON INJECTION DATE(cm)	0.75	0.65	0.90	0.60	
85	18 DATE ANIMAL SACRIFICED	--	--	--	--	
90	19 LENGTH OF TUMOR ON SACRIFICE DATE(cm)	1.40	1.80	1.80	1.00	
95	20 WIDTH OF TUMOR ON SACRIFICE DATE(cm)	1.00	1.05	1.40	1.10	
100	21 DEPTH OF TUMOR ON SACRIFICE DATE(cm)	0.80	0.70	0.80	0.75	
105	22 LENGTH OF EFFECT UPON TUMOR ON SACRIFICE DATE(cm)	1.40	1.60	1.60	1.00	
110	23 WIDTH OF EFFECT UPON TUMOR ON SACRIFICE DATE(cm)	1.00	1.05	1.10	1.10	
115	24 DEPTH OF EFFECT UPON TUMOR ON SACRIFICE DATE(cm)	0.80	0.45	0.60	0.70	
120	25 COMMENTS AS RESULT OF TUMOR ASSESSMENT	red skin 1.3 x 1.0cm; some muscle damage	skin effect 1.6 x 1.2cm; some mus- cle damage	skin effect 1.4 x 1.4cm	skin effect 0.9 x 0.9cm some mus- cle damage	skin effect 1.5 x 1.4 cm

50

The results of Table IV - IX are summarized in Table X.

5

10

15

20

25

30

35

40

45

50

55

TABLE X

compound	mean dose mg/kg	method of injection	tumor size in mm	tumor size in mm	light intensity ni/l/cm <sup>2</sup>	light absorpt. J/cm <sup>2</sup>	wave- length nm	$\bar{x} \pm s.d.$ (cm)	range cm
mono-1-aspartyl chlorin e6	100	iv	24	24	Sar-T	200	300	665	(5) 0.51±0.12
mono-1-cysteinyl chlorin e6	100	iv	24	24	Sar-T	200	300	665	(5) 0.66±0.14
mono-1-seriny1-2-acetyl chlorin e6	100	iv	24	24	Sar-T	200	300	660	(2) 0.00
mono-1-seriny1-2-formyl chlorin e6	100	iv	24	24	Sar-T	200	300	690	(4) 0.10±0.13
mono-1-seriny1 deuterocchlorin e6	100	iv	24	24	Sar-T	200	300	655	(5) 0.15±0.09
mono-1-seriny1 mesochlorin e6	100	iv	24	24	Sar-T	200	300	651	(5) 0.12±0.13
									0.00-0.30

TABLE XI - MOUSE DATA

	Compound Used Mono-L- -seriryl chlorin eG					
1	ANIMAL GROUP NO.	49	49	49	49	49
5	2 DATE EXPERIMENT STARTED	--	--	--	--	--
3	MOUSE NO.	1	2	3	4	5
4	SEX OF MOUSE	m	f	f	f	f
5	WT. OF MOUSE (gms)	24.8	22.1	20.2	16.4	20.7
10	6 DRUG DOSE (mg/kg)	100.0	100.0	100.0	100.0	100.0
7	7 METHOD OF DRUG INTRODUCTION	iv	iv	iv	iv	iv
8	8 TIME BETW. DRUG INTRODUCTION + LIGHT TREATMENT (hrs)	24.0	24.0	24.0	24.0	24.0
9	9 TUMOR TYPE	SMT-F	SMT-F	SMT-F	SMT-F	SMT-F
15	10 POSITION OF TUMOR ON ANIMAL	r leg	r leg	r leg	r leg	r leg
11	11 LIGHT TREATMENT INTENSITY (mV/cm <sup>2</sup> )	75.0	75.0	75.0	75.0	75.0
12	12 LIGHT DOSE (J/cm <sup>2</sup> )	20.0	20.0	20.0	20.0	20.0
20	13 WAVE LENGTH USED TO TREAT TUMOR (nm)	665	665	665	665	665
14	14 DATE ANIMAL INJECTED WITH DRUG	--	--	--	--	--
25	15 LENGTH OF TUMOR ON INJECTION DATE (cm)	0.00	1.40	2.00	1.50	1.60
16	16 WIDTH OF TUMOR ON INJECTION DATE (cm)	0.00	0.80	1.00	0.90	1.05
17	17 DEPTH OF TUMOR ON INJECTION DATE (cm)	0.00	0.65	0.60	0.60	0.65
30	18 DATE ANIMAL SACRIFICED	--	--	--	--	--
19	19 LENGTH OF TUMOR ON SACRIFICE DATE (cm)	0.00	1.60	2.20	1.90	1.20
20	20 WIDTH OF TUMOR ON SACRIFICE DATE (cm)	0.00	0.85	1.15	1.15	1.05
35	21 DEPTH OF TUMOR ON SACRIFICE DATE (cm)	0.00	0.45	0.65	0.60	0.80
22	22 LENGTH OF EFFECT UPON TUMOR ON SACRIFICE DATE (cm)	0.00	1.60	1.20	1.50	1.20
40	23 WIDTH OF EFFECT UPON TUMOR ON SACRIFICE DATE (cm)	0.00	0.85	1.00	1.20	1.05
24	24 DEPTH OF EFFECT UPON TUMOR ON SACRIFICE DATE (cm)	0.00	0.45	0.50	0.50	0.50
45	25 COMMENTS AS RESULT OF TUMOR ASSESSMENT	Died of the ether	leg swollen, skin pink over the treatment area, top 2/3 of tumor red.	leg swollen, skin pink over treatment area, tumor red on top.	leg swollen, skin pink over treatment site, tumor red on top.	leg swollen, skin pink over treatment site, top 2/3 of tumor red.

50

55

TABLE XI - MOUSE DATA (cont.)

COMPOUND USED	Mono-L- -serinyl chlorin e6				
1 ANIMAL GROUP NO.	49	49	49	49	49
2 DATE EXPERIMENT STARTED	--	--	--	--	--
3 MOUSE NO.	7	8	9	10	11
4 SEX OF MOUSE	f	f	f	f	m
5 WT. OF MOUSE (gms)	20.9	19.4	20.6	20.2	19.6
6 DRUG DOSE (mg/kg)	100.0	100.0	100.0	100.0	100.0
7 METHOD OF DRUG INTRODUCTION	iv	iv	iv	iv	iv
8 TIME BETW. DRUG INTRODUCTION + LIGHT TREATMENT (hrs)	24.0	24.0	24.0	24.0	0.0
9 TUMOR TYPE	SMT-F	SMT-F	SMT-F	SMT-F	0.0
10 POSITION OF TUMOR ON ANIMAL	r leg	r leg	r leg	r leg	0.0
11 LIGHT TREATMENT INTENSITY (mW/cm <sup>2</sup> )	75.0	75.0	75.0	75.0	0.0
12 LIGHT DOSE (J/cm <sup>2</sup> )	20.0	20.0	20.0	20.0	0.0
13 WAVE LENGTH USED TO TREAT TUMOR (nm)	665	665	665	665	0.0
14 DATE ANIMAL INJECTED WITH DRUG	--	--	--	--	--
15 LENGTH OF TUMOR ON INJECTION DATE (cm)	1.50	0.90	1.70	1.30	0.00
16 WIDTH OF TUMOR ON INJECTION DATE (cm)	1.25	0.75	0.95	0.90	0.00
17 DEPTH OF TUMOR ON INJECTION DATE (cm)	0.70	0.70	0.65	0.60	0.00
18 DATE ANIMAL SACRIFICED	--	--	--	--	--
19 LENGTH OF TUMOR ON SACRIFICE DATE (cm)	1.90	1.45	1.70	1.70	0.00
20 WIDTH OF TUMOR ON SACRIFICE DATE (cm)	1.35	0.95	1.00	1.10	0.00
21 DEPTH OF TUMOR ON SACRIFICE DATE (cm)	0.85	0.80	0.95	0.85	0.00
22 LENGTH OF EFFECT UPON TUMOR ON SACRIFICE DATE (cm)	1.50	1.30	1.40	1.10	0.00
23 WIDTH OF EFFECT UPON TUMOR ON SACRIFICE DATE (cm)	1.00	0.95	0.90	0.95	0.00
24 DEPTH OF EFFECT UPON TUMOR ON SACRIFICE DATE (cm)	0.70	0.60	0.60	0.45	0.00
25 COMMENTS AS RESULT OF TUMOR ASSESSMENT	leg swollen, skin pink over treatment site, top 1/2 of tumor red	leg swollen, skin pink over treatment area, top 2/3 of tumor red	leg swollen, skin pink over treatment site, top 2/3 of tumor red	leg swollen, skin pink over treatment area, top 1/2 of tumor red	died of ether after the injection

TABLE XII - MOUSE DATA

COMPOUND USED	Mono glycyl chlorin e6				
1 ANIMAL GROUP NO.	47	47	47	47	47
2 DATE EXPERIMENT STARTED	--	--	--	--	--
3 MOUSE NO.	1	2	3	4	5
4 SEX OF MOUSE	f	f	f	f	f
5 WT. OF MOUSE (gms)	20.4	18.7	21.3	19.6	18.4
6 DRUG DOSE (mg/kg)	100.0	100.0	100.0	100.0	100.0
7 METHOD OF DRUG INTRODUCTION	iv	iv	iv	iv	iv
8 TIME BETW. DRUG INTRODUCTION + LIGHT TREATMENT (hrs)	24.0	24.0	24.0	24.0	24.0
9 TUMOR TYPE	SMT-F	SMT-F	SMT-F	SMT-F	SMT-F
10 POSITION OF TUMOR ON ANIMAL	r leg	r leg	r leg	r leg	r leg
11 LIGHT TREATMENT INTENSITY (mW/cm <sup>2</sup> )	75.0	75.0	75.0	75.0	75.0
12 LIGHT DOSE (J/cm <sup>2</sup> )	20.0	20.0	20.0	20.0	20.0
13 WAVE LENGTH USED TO TREAT TUMOR (nm)	665	665	665	665	665
14 DATE ANIMAL INJECTED WITH DRUG	--	--	--	--	--
15 LENGTH OF TUMOR ON INJECTION DATE (cm)	1.60	1.10	1.80	1.85	1.35
16 WIDTH OF TUMOR ON INJECTION DATE (cm)	1.00	0.95	1.10	1.50	1.05
17 DEPTH OF TUMOR ON INJECTION DATE (cm)	0.80	0.65	0.60	0.85	0.65
18 DATE ANIMAL SACRIFICED	--	--	--	--	--
19 LENGTH OF TUMOR ON SACRIFICE DATE (cm)	1.20	0.00	1.65	1.40	1.25
20 WIDTH OF TUMOR ON SACRIFICE DATE (cm)	0.90	0.00	1.40	1.00	0.95
21 DEPTH OF TUMOR ON SACRIFICE DATE (cm)	0.90	0.00	1.00	0.90	0.65
22 LENGTH OF EFFECT UPON TUMOR ON SACRIFICE DATE (cm)	0.70	0.00	0.40	0.30	0.70
23 WIDTH OF EFFECT UPON TUMOR ON SACRIFICE DATE (cm)	0.60	0.00	0.60	0.60	0.80
24 DEPTH OF EFFECT UPON TUMOR ON SACRIFICE DATE (cm)	0.30	0.00	0.20	0.20	0.25
25 COMMENTS AS RESULT OF TUMOR ASSESSMENT		died from the dye injection; cannot read			

50

55

TABLE XII - MOUSE DATA (cont.)

	Mono glycyl chloran e6				
1	ANIMAL GROUP NO.	47	47	47	47
5	2 DATE EXPERIMENT STARTED	--	--	--	--
3	MOUSE NO.	6	7	8	9
4	SEX OF MOUSE	f	f	f	f
5	WT. OF MOUSE (gms)	19.6	19.1	20.1	19.8
10	6 DRUG DOSE (mg/kg)	100.0	100.0	100.0	100.0
7	7 METHOD OF DRUG INTRODUCTION	iv	iv	iv	iv
8	8 TIME PTW. DRUG INTRODUCTION + LIGHT TREATMENT (hrs)	24.0	24.0	24.0	24.0
9	9 TUMOR TYPE	SMT-F	SMT-F	SMT-F	SMT-F
15	10 POSITION OF TUMOR ON ANIMAL	r leg	r leg	r leg	r leg
11	11 LIGHT TREATMENT INTENSITY (mW/cm <sup>2</sup> )	75.0	75.0	75.0	75.0
12	12 LIGHT DOSE (J/cm <sup>2</sup> )	20.0	20.0	20.0	20.0
20	13 WAVE LENGTH USED TO TREAT TUMOR (nm)	665	665	665	665
14	14 DATE ANIMAL INJECTED WITH DRUG	--	--	--	--
15	15 LENGTH OF TUMOR ON INJECTION DATE (cm)	1.30	1.35	1.35	1.35
25	16 WIDTH OF TUMOR ON INJECTION DATE (cm)	0.95	1.00	0.90	1.05
17	17 DEPTH OF TUMOR ON INJECTION DATE (cm)	0.70	0.80	0.60	0.60
30	18 DATE ANIMAL SACRIFICED	--	--	--	--
19	19 LENGTH OF TUMOR ON SACRIFICE DATE (cm)	1.05	1.35	1.40	1.35
20	20 WIDTH OF TUMOR ON SACRIFICE DATE (cm)	1.00	1.00	1.10	1.00
35	21 DEPTH OF TUMOR ON SACRIFICE DATE (cm)	0.65	0.90	0.80	0.80
22	22 LENGTH OF EFFECT UPON TUMOR ON SACRIFICE DATE (cm)	0.00	0.75	0.00	0.00
23	23 WIDTH OF EFFECT UPON TUMOR ON SACRIFICE DATE (cm)	0.00	0.80	0.00	0.00
40	24 DEPTH OF EFFECT UPON TUMOR ON SACRIFICE DATE (cm)	0.00	0.90	0.00	0.00
25	25 COMMENTS AS RESULT OF TUMOR ASSESSMENT	no effect	not clear if the effect is due to the treatment.	no effect	no effect
45					

50

The results Of Table XI - XII are summarized in Table XIII.

5

10

15

20

25

30

35

40

45

TABLE XIII

Compound	Drug Dose mg/kg	Tumor Type	Time in Hrs. between drug introduction & Light Treatment	Position of tumor in animal	Light Intensity in mV/cm <sup>2</sup>	Light Dose used to treat tumors in J/cm <sup>2</sup>	Depth in cm of tumors effect upon tumor	S.D.	n	range
L-α mono-	100	Smt-f	24	rt. leg	75.0	20.0	665	0.53 ± 0.09	9	0.45-0.70
serinyl chlorin e <sub>6</sub>										
L-α monoglycl	100	Smt-f	24	rt. leg	75.0	20.0	665	0.15 ± 0.13	8	0.0-0.3
chlorin e <sub>6</sub>										

50 The preparation of pharmacological dosages for the administration of the active ingredient, that is the amino acid porphyrin adducts, which were prepared in Examples 1-21 hereinabove, is as follows:

#### EXAMPLE XXIV

55 A tablet base was prepared by blending the following ingredient in the proportion by weight indicated:

5

	Grams
Sucrose, USP	80.3
Tapioca Starch	13.2
Magnesium Stearate	4.4

Into this base, there was blended sufficient amino acid porphyrin adducts to provide tablets each containing 100 mg. of active ingredient.

10

#### EXAMPLE XXV

A blend was prepared containing the following ingredients:

15

Calcium phosphate	17.6
Dicalcium phosphate	18.8
Magnesium trisilicate, USP	5.2
Lactose, U.S.P.	5.2
Potato Starch	5.2
Magnesium Stearate A	0.8
Magnesium Stearate B	0.32
Porphyrin Amino Acid Adducts	20

20

25

This blend was divided and formed into capsules each containing 25 mg of active ingredient.

#### EXAMPLE XXVI

30

To a commercially available raspberry flavored sugar syrup is added the equivalent of 40 mg of the amino acid porphyrin adduct per milliliter and the mixture is homogenized in a mechanical device for this purpose. This mixture is especially suitable for oral administration containing 200 mg of the active ingredient.

#### EXAMPLE XXVII

35

A sterile solution of the following composition is prepared: 200 mg of the sodium salt of the amino acid porphyrin adduct is dissolved in a 0.9% NaCl solution so that the final concentration is 20 mg/ml.

This solution is suitable for I.V. and I.M. administration.

40

#### EXAMPLE XXVIII

The sodium salt of the amino acid porphyrin adduct is dissolved in 0.9% NaCl solution so that the final concentration is 5 mg/ml. This is placed in an aerosol dispenser with a hydrocarbon propellant. This preparation is suitable for topical application.

45

#### EXAMPLE XXIX

#### PREPARATION OF A METAL SALT

50

The sodium salt of the porphyrin amino acid adduct is prepared by dissolving said adduct in water containing an equimolar amount of sodium hydroxide and freeze drying the resulting mixture.

In this fashion, other metal salts are prepared including potassium, calcium, and lithium salts.

55

#### PREPARATION OF AN ACID SALT

The amino acid porphyrin adduct described in the preceding examples are converted to acid salts, e.g., hydrochloride, by dissolving in an aqueous solution containing an equivalent amount of acid, e.g., hydrochloric acid, and the solution is evaporated to dryness to obtain the solid salt. Alternately, alcoholic solutions of hydrogen chloride gas, dissolved in ethanol can be used in lieu of the aqueous acid solution.

and the acid salt is obtained by evaporation of the solvent or crystallization from the alcohol, e.g., by addition of a non-solvent.

**Claims**

5 **Claims for the following Contracting States : BE, CH, DE, FR, GB, IT, LI, LU, NL, SE**


1. A therapeutic composition comprising a fluorescent mono, di or polyamide of an aminomonocarboxylic acid and a tetrapyrrole compound of the formula:

10

15

20

25




or salt thereof

30 or the corresponding di- or tetrahydrotetrapyrroles and a pharmaceutically acceptable carrier therefor;  
wherein:


R<sub>1</sub> is methyl;

35




40 or

45




R<sub>2</sub> is H, vinyl, ethyl,


50



55 acetyl,




5



10

$\text{CH}_2\text{CH}_2\text{CO}_2\text{H}$ , or  $=\text{CHCHO}$ ;  
 $R_3$  is methyl


15



20

or

25




30

 $R_4$  is H, vinyl, ethyl,

35

 $\text{CH}_2\text{CH}_2\text{CO}_2\text{H}$ ,  $=\text{CHCHO}$ ; or


40




45

$R_5$  is methyl;  
 $R_6$  is H,  $\text{CH}_2\text{CH}_2\text{CO}_2\text{H}$ ,  $\text{CH}_2\text{CH}_2\text{CO}_2\text{R}$  or  $\text{CO}_2\text{H}$ ;  
 $R_7$  is  $\text{CH}_2\text{CH}_2\text{CO}_2\text{H}$ ,  $\text{CH}_2\text{CH}_2\text{CO}_2\text{R}$ , or

50

 $R_8$  is methyl or

55



$R_3$  is H, COOH,  $\text{CH}_2\text{COOH}$  or methyl;  
 provided that when  $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$ ,  $R_7$  and  $R_8$  represent two substituents or are divalent and attached to the same carbon, the respective pyrrol ring to which they are attached is a dihydropyrrole;

5         $R$  is lower alkyl or benzyl;  
 with the proviso that at least one of  $R_1$ - $R_8$  includes a free carboxyl group, and that amide bonds (1 to 4) are formed between the amino group of the aminomonocarboxylic acid and one of the carboxy groups of the tetrapyrrole; with the proviso that the tetrapyrrole residue is not pheophorbide a.

- 2. The composition according to claim 1 wherein the amino acid is an alpha amino acid.
- 10     3. Composition according to claim 1 or 2 wherein the tetrapyrrole is a porphyrin, chlorin or bacteriochlorin.
- 4. Composition according to any of claims 1 to 3, wherein the amide-containing substituents are asymmetrically arranged on the tetrapyrrole molecule.

15     5. Composition according to claim 1 wherein the amide is:

diseranyl mesoporphyrin IX,

20     diglycyl mesoporphyrin IX,

di- $\alpha$ -(DL)-alanyl mesoporphyrin IX,

di- $\beta$ -alanyl mesoporphyrin IX,

25     di- $\epsilon$ -amino-n-caproyl mesoporphyrin IX,

diglycyl trans-mesochlorin IX,

30     diglycyl trans-mesochlorin e<sub>6</sub>,

diglycyl mesochlorin e<sub>4</sub>,

diglycyl hematoporphyrin IX,

35     diglycyl chlorin e<sub>6</sub>,

diglycyl protoporphyrin IX,

40     diglycyl deuteroporphyrin,

di- $\alpha$ -(DL)-alanyl trans-mesochlorin IX,

45     di- $\alpha$ -(DL)-alanyl mesochlorin e<sub>6</sub>,

di- $\alpha$ -(DL)-alanyl mesochlorin e<sub>4</sub>,

di- $\alpha$ -(DL)-alanyl hematoporphyrin IX,

50     di- $\alpha$ -(DL)-alanyl chlorin e<sub>6</sub>,

di- $\alpha$ -(DL)-alanyl protoporphyrin IX,

55     di- $\alpha$ -(DL)-alanyl deuteroporphyrin,

di- $\beta$ -(DL)-alanyl trans-mesochlorin IX,


di- $\beta$ -(DL)-alanyl mesochlorin e<sub>6</sub>,

- di- $\beta$ -(DL)-alanyl mesochlorin 4,  
5 di- $\beta$ -(DL)-alanyl hematoporphyrin IX,  
di- $\beta$ -(DL)-alanyl chlorin e<sub>6</sub>,  
10 di- $\beta$ -(DL)-alanyl protoporphyrin IX,  
di- $\beta$ -(DL)-alanyl deuteroporphyrin,  
di-L- $\alpha$ -serinyl chlorin e<sub>6</sub>,  
15 di-L- $\alpha$ -serinyl trans-mesochlorin e<sub>6</sub>,  
di-L- $\alpha$ -serinyl trans-mesochlorin IX,  
di-L- $\alpha$ -serinyl trans-mesochlorin e<sub>4</sub>,  
20 di-L- $\alpha$ -serinyl hematoporphyrin IX,  
di-L- $\alpha$ -serinyl protoporphyrin IX,  
di-L- $\alpha$ -serinyl deuteroporphyrin,  
25 di- $\epsilon$ -amino-n-caproyl-hematoporphyrin IX,  
di- $\epsilon$ -amino-n-caproyl-chlorin e<sub>6</sub>,  
30 di- $\epsilon$ -amino-n-caproyl-protoporphyrin IX,  
di- $\epsilon$ -amino-n-caproyl-deuteroporphyrin,  
mono-L-serinyl mesochlorin e<sub>6</sub>,  
35 mono-L-serinyl Deuterochlorin e<sub>6</sub>,  
mono-L-serinyl-2-formyl chlorin e<sub>6</sub>,  
40 mono-L-serinyl-2-acetyl chlorin e<sub>6</sub>,  
mono-L-cysteinyl chlorin e<sub>6</sub>,  
mono-L-asparaginyl chlorin e<sub>6</sub>,  
45 mono serinyl chlorin e<sub>6</sub>,  
mono-(DL)glycyl chlorin e<sub>6</sub>,  
50 alanyl chlorin e<sub>6</sub>,  
mono-L-valyl chlorin e<sub>6</sub>,  
mono-L-leucyl chlorin e<sub>6</sub>,  
55 mono-L-isoleucyl chlorin e<sub>6</sub>,  
mono-L-prolyl chlorin e<sub>6</sub>,

- mono-L-methionyl chlorin e<sub>6</sub>,
- 5 mono-L-threoninyl chlorin e<sub>6</sub>,
- tyrosyl chlorin e<sub>6</sub>,
- 10 glutaminyl chlorin e<sub>6</sub>,
- lysyl chlorin e<sub>6</sub>,
- arginyl chlorin e<sub>6</sub>,
- 15 histidyl chlorin e<sub>6</sub>,
- β-alanyl chlorin e<sub>6</sub>,
- mono-ε-amino-n-caproyl chlorin e<sub>6</sub>,
- 20 monoglycyl mesoporphyrin IX,
- mono alanyl mesoporphyrin IX,
- mono-β-alanyl mesoporphyrin IX,
- 25 mono-ε-amino-n-caproyl mesoporphyrin IX,
- mono-β-alanyl-hematoporphyrin IX,
- 30 threoninyl-2-formylchlorin e<sub>6</sub>,
- mono-L-threoninyl deuterochlorin e<sub>6</sub>, or
- mono-L-threoninyl mesochlorin e<sub>6</sub>,
- 35
6. Use of a fluorescent mono, di or polyamide of an aminomonocarboxylic acid and a tetrapyrrole containing one or two carboxy groups of the structure as claimed in any of claims 1 to 5, or a salt thereof, and a pharmaceutically acceptable carrier therefor, for the preparation of a therapeutic composition for photodiagnosis and/or phototherapy of tumors.
- 40
- Claims for the following Contracting State : AT**
1. Use of a fluorescent mono, di or polyamide of an aminomonocarboxylic acid and a tetrapyrrole compound of the formula:
- 45

50

55




or salt thereof  
or the corresponding di- or tetrahydrotetrapyrroles, and a pharmaceutically acceptable carrier therefor;

wherein

R<sub>1</sub> is methyl;


25



30


or

35



R<sub>2</sub> is H, vinyl, ethyl,


40




45

acetyl,

50




55




$\text{CH}_2\text{CH}_2\text{CO}_2\text{H}$ , or  $=\text{CHCHO}$ ;  
 $\text{R}_3$  is methyl

5




10 or

15




$\text{R}_4$  is H, vinyl, ethyl;

20


25  $\text{CH}_2\text{CH}_2\text{CO}_2\text{H}$ ,  $=\text{CHCHO}$ ; or

30



$\text{R}_5$  is methyl;  
 $\text{R}_6$  is H,  $\text{CH}_2\text{CH}_2\text{CO}_2\text{H}$ ,  $\text{CH}_2\text{CH}_2\text{CO}_2\text{R}$  or  $\text{CO}_2\text{H}$ ;  
 $\text{R}_7$  is  $\text{CH}_2\text{CH}_2\text{CO}_2\text{H}$ ,  $\text{CH}_2\text{CH}_2\text{CO}_2\text{R}$ , or


35



40

$\text{R}_8$  is methyl or

45



50

$\text{R}_9$  is H, COOH,  $\text{CH}_2\text{COOH}$  or methyl;  
provided that when  $\text{R}_1$ ,  $\text{R}_2$ ,  $\text{R}_3$ ,  $\text{R}_4$ ,  $\text{R}_7$  and  $\text{R}_8$  represent two substituents or are divalent and attached to the same carbon, the respective pyrrole ring to which they are attached is a dihydropyrrole;

R is lower alkyl or benzyl;


with the proviso that at least one of  $\text{R}_1$ - $\text{R}_9$  includes a free carboxyl group, and that amide bonds (1 to 4) are formed between the amino group of the aminomonocarboxylic acid and one of the carboxy groups of the tetrapyrrole; with the proviso that the tetrapyrrole residue is not pheophorbide a; for the preparation of a therapeutic composition for photodiagnosis and/or phototherapy of tumors.

2. Use according to claim 1, characterized in, that the amino acid is an alpha amino acid.


## Patentansprüche

Patentansprüche für folgende Vertragsstaaten : BE, CH, DE, FR, GB, IT, LI, LU, NL, SE


1. Therapeutische Zusammensetzung, enthaltend ein fluoreszierendes Mono-, Di- oder Polyamid einer Aminomonocarbonsäure und einer Tetrapyrrol-Verbindung der Formel



oder eines Salzes davon  
oder der entsprechenden Di- oder Tetrahydrotetrapyrrole, und einen pharmazeutisch akzeptablen Träger dafür, wobei

R<sub>1</sub> Methyl,


oder



ist;


R<sub>2</sub> Wasserstoff, Vinyl, Ethyl,

Acetyl,



$\text{CH}_2\text{CH}_2\text{CO}_2\text{H}$  oder =  $\text{CHCHO}$  ist;  
 $\text{R}_3$  Methyl.


5



10

oder

15




ist;

20  $\text{R}_4$  Wasserstoff, Vinyl, Ethyl,

25

CH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>H, = CHCHO oder

30




35

ist;

 $\text{R}_5$  Methyl ist; $\text{R}_6$  Wasserstoff,  $\text{CH}_2\text{CH}_2\text{COH}$ ,  $\text{CH}_2\text{CH}_2\text{CO}_2\text{R}$  oder  $\text{CO}_2\text{H}$  ist; $\text{R}_7$   $\text{CH}_2\text{CH}_2\text{CO}_2\text{H}$ ,  $\text{CH}_2\text{CH}_2\text{CO}_2\text{R}$  oder

40




45

ist;

 $\text{R}_8$  Methyl oder

50



55

ist;

$R_9$  Wasserstoff, COOH, CH<sub>2</sub>, CH<sub>2</sub>COOH oder Methyl ist; unter der Voraussetzung, daß, wenn R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>7</sub> und R<sub>8</sub> zw i Substituenten darstellen oder divalent sind und am gleichen Kohlenstoff gebunden ist, der betreffende Pyrrolring, an den si gebunden sind, ein Dihydropyrrol ist;

R ein niedriger s Alkyl oder Benzyl ist;

5 unter der Voraussetzung, daß mind stens einer von R<sub>1</sub> - R<sub>9</sub> ein freie Carboxylgruppe enthält, und daß zwischen der Aminogruppe der Aminomonocarbonsäure und den Carboxygruppen des Tetrapyrrolo Amidbindungen (1 bis 4) gebildet werden; unter der Voraussetzung daß der Tetrapyrrolrest nicht Pheophorbid a ist.

10 2. Zusammensetzung nach Anspruch 1, in der die Aminosäure eine alpha-Aminosäure ist.

Di- $\alpha$ -Serinyl-trans-mesochlorin IX  
Di-L- $\alpha$ -Serinyl-trans-Mesochlorin e<sub>6</sub>  
Di-L- $\alpha$ -Serinyl-Hematoporphyrin IX  
Di-L- $\alpha$ -Serinyl-Protoporphyrin IX  
15 Di-L- $\alpha$ -Serinyl-Deuteroporphyrin  
Di- $\epsilon$ -Amino-n-Caproyl-Hematoporphyrin IX  
Di- $\epsilon$ -Amino-n-Caproyl-Chlorin e<sub>6</sub>  
Di- $\epsilon$ -Amino-n-Caproyl-Protoporphyrin IX  
Di- $\epsilon$ -Amino-n-Caproyl-Deuteroporphyrin

20 Mono-L-Serinyl-Mesochlorin e<sub>6</sub>  
Mono-L-Serinyl-Deuterochlorin e<sub>6</sub>  
Mono-L-Serinyl-2-Formyl-Chlorin e<sub>6</sub>  
Mono-L-Serinyl-2-Acetyl-Chlorin e<sub>6</sub>  
Mono-L-Cysteinyl-Chlorin e<sub>6</sub>

25 Mono-L-Asparaginyl-Chlorin e<sub>6</sub>  
Mono-Serinyl-Chlorin e<sub>6</sub>  
Mono-(DL)-Glycyl-Chlorin e<sub>6</sub>  
Alanyl-Chlorin e<sub>6</sub>  
Mono-L-Valyl-Chlorin e<sub>6</sub>

30 Mono-L-Leucyl-Chlorin e<sub>6</sub>  
Mono-L-Isoleucyl-Chlorin e<sub>6</sub>  
Mono-L-Prolyl-Chlorin e<sub>6</sub>  
Mono-L-Methionyl-Chlorin e<sub>6</sub>  
Mono-L-Threoninyl-Chlorin e<sub>6</sub>

35 Tyrosyl-Chlorin e<sub>6</sub>  
Glutaminyl-Chlorin e<sub>6</sub>  
Lysyl-Chlorin e<sub>6</sub>  
Arginyl-Chlorin e<sub>6</sub>  
Histidyl-Chlorin e<sub>6</sub>  
40  $\beta$ -Alanyl-Chlorin e<sub>6</sub>  
Mono- $\epsilon$ -Amino-n-Caproyl-Chlorin e<sub>6</sub>  
Monoglycyl-Mesoporphyrin IX  
Mono-Alanyl-Mesoporphyrin IX  
Mono- $\beta$ -Alanyl-Mesoporphyrin IX

45 Mono- $\epsilon$ -Amino-n-Caproyl-Mesoporphyrin IX  
Mono- $\beta$ -Alanyl-Hematorporphyrin IX  
Threoninyl-2-Formylchlorin e<sub>6</sub>

50 3. Zusammensetzung nach Anspruch 1 oder Anspruch 2, in der das Tetrapyrrol ein Porphyrin, Chlorin oder Bacteriochlorin ist.

4. Zusammensetzung nach einem der Ansprüche 1 bis 3, in der die Amid-haltigen Substituenten asymmetrisch am Tetrapyrrol-Molekül angeordnet sind.

55 5. Zusammensetzung nach Anspruch 1, in der das Amid

Diserinyl-Mesophosphyrin IX  
Diglycyl-Mesoporphyrin IX

Di- $\alpha$ -(D,L)-Alanyl-Mesoporphyrin IX  
 Di- $\beta$ -Alanyl-Mesoporphyrin IX  
 Di- $\epsilon$ -Amino-n-Caproyl-Mesoporphyrin IX  
 Diglycyl-trans-Mesochlorin IX  
 5      Di-glycyl-trans-Mesochlorin e<sub>6</sub>  
 Di-glycyl-Mesoschlorin e<sub>4</sub>  
 Di-glycyl-Hemaporphyrin IX  
 Di-glycyl-Chlorin e<sub>6</sub>  
 Di-glycyl-Protoporphyrin IX  
 10     Di-glycyl-Deuteroporphyrin  
 Di- $\alpha$ -(DL)-Alanyl-trans-Mesochlorin IX  
 Di- $\alpha$ -(DL)-Alanyl-Mesochlorin e<sub>5</sub>  
 Di- $\alpha$ -(DL)-Alanyl-Mesochlorin e<sub>4</sub>  
 Di- $\alpha$ -(DL)-Alanyl-Hematoporphyrin IX  
 15     Di- $\alpha$ -(DL)-Alanylchlorin e<sub>5</sub>  
 Di- $\alpha$ -(DL)-Alanyl-Protoporphyrin IX  
 Di- $\alpha$ -(DL)-Alanyl-Deuteroporphyrin  
 Di- $\beta$ -(DL)-Alanyl-trans-Mesochlorin IX  
 Di- $\beta$ -(DL)-Alanyl-Mesochlorin e<sub>5</sub>  
 20     Di- $\beta$ -(DL)-Alanyl-Mesochlorin e<sub>4</sub>  
 Di- $\beta$ -(DL)-Alanyl-Hematoporphyrin IX  
 Di- $\beta$ -(DL)-Alanyl-Chlorin e<sub>5</sub>  
 Di- $\beta$ -(DL)-Alanyl-Protoporphyrin IX  
 Di-L- $\alpha$ -Serinyl-trans-Mesochlorin e<sub>5</sub>  
 25     Mono-L-Threoninyl-Deuterochlorin e<sub>6</sub> oder  
 Mono-L-Threoninyl-Mesochlorin e<sub>5</sub>

ist.

- 30 6. Verwendung eines fluoreszierenden Mono-, Di- oder Polyamids einer Aminomonocarbonsäure und eines Tetrapyrrols, das eine oder zwei Carboxygruppen enthält, gemäß der in einem der Ansprüche 1 bis 5 beanspruchten Struktur, oder eines Salzes davon, und eines pharmazeutisch akzeptablen Trägers dafür, zur Herstellung einer therapeutischen Zusammensetzung für Photodiagnose und/oder für Phototherapie von Tumoren.

35

**Patentansprüche für folgenden Vertragsstaat : AT**


1. Verwendung eines fluoreszierenden Mono-, Di- oder Polyamids einer Aminomonocarbonsäure und einer Tetrapyrrol-Verbindung der Formel

40

45

50

55



oder ein s Salzes davon,  
oder der entsprechenden Di- oder Tetrapyrrol und eines pharmazeutisch akzeptablen Trägers dafür,  
wobei

R<sub>1</sub> Methyl;

5



10



oder

15



20

ist;

R<sub>2</sub> Wasserstoff, Vinyl, Ethyl,

25



Acetyl,

30



35

-Ethyl,

40



-CH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>H oder = CHCHO ist;  
R<sub>3</sub> Methyl,


45



50

oder

55




ist;

**R<sub>4</sub>** Wasserstoff, Vinyl, Ethyl.

5

**-CH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>H**, =CHCHO oder

10




15

ist;

**R<sub>5</sub>** Methyl ist;**R<sub>6</sub>** Wasserstoff, -CH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>H, CH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>R oder CO<sub>2</sub>H ist;**R<sub>7</sub>** CH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>H, CH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>R oder

20




25

ist;

**R<sub>8</sub>** Methyl oder

30



35

ist;

**R<sub>9</sub>** Wasserstoff, COOH, CH<sub>2</sub>COOH oder Methyl ist;unter der Voraussetzung, daß, wenn R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>7</sub> und R<sub>8</sub> zwei Substituenten darstellen oder divalent und am gleichen Kohlenstoff gebunden sind, der betreffende Pyrrolring, an den sie gebunden sind, ein Dihydropyrrol ist;**R** ist ein niedrigeres Alkyl oder Benzyl,unter der Voraussetzung, daß mindestens einer von R<sub>1</sub> bis R<sub>9</sub> eine freie Carboxylgruppe enthält, und daß zwischen der Aminogruppe der Aminomonocarbonsäure und einer der Carboxygruppen des Tetrapyrrolo-Amidverbindungen (1 bis 4) gebildet werden; unter der Voraussetzung, daß der Tetrapyrrolring nicht Pheophorbid a ist;

zur Herstellung einer therapeutischen Zusammensetzung für Fotodiagnose und/oder die Fototherapie von Tumoren.

40

45

2. Verwendung gemäß Anspruch 1,

50


dadurch gekennzeichnet,

daß die Aminosäure eine alpha-Aminosäure ist.

**Revendications****R** vendications pour les Etats contractants suivants : BE, CH, DE, FR, GB, IT, LI, LU, NL, SE


55

1. Composition thérapeutique comprenant un mono-, di- ou polyamide fluorescent d'un acide aminomonocarboxylique et d'un composé de tétrapyrrole représenté par la formule :




ou un sel de celui-ci,  
ou les di- ou tétrahydrotétrapyrroles correspondants ; et  
un support pharmaceutiquement acceptable pour celui-ci ;  
où :

- R<sub>1</sub> représente méthyle.



30

ou



40 - R<sub>2</sub> représente H, vinyle, éthyle,



45


acétyle,



55


CH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>H, ou = CHCHO ;

5



- R<sub>3</sub> représente méthyle,


10



15

ou

20



- R<sub>4</sub> représente H, vinyle, éthyle,


25



30




35



40


- R<sub>5</sub> représente méthyle ;
- R<sub>6</sub> représente H, CH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>H, CH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>R ou CO<sub>2</sub>H ;
- R<sub>7</sub> représente CH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>H, CH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>R, ou

45



- R<sub>8</sub> représente méthyle ou

50



55


- R<sub>9</sub> représentent H, COOH, CH<sub>2</sub>COOH ou méthyle ;  
à la condition que, lorsque R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>7</sub> et R<sub>8</sub> représentent deux substituants ou sont bivalents et attachés au même carbone, le noyau pyrrole r spectif auquel ils sont attachés est un dihydropyrrole ;

- R r présente alkyle inférieur ou benzyle ; avec la condition qu'au moins l'un parmi R<sub>1</sub>-R<sub>3</sub> comprenne un groupe carboxyle libre, et qu' des liaisons amide (1 à 4) soient formées entre l' groupe amino de l'acide aminomonocarboxylique et l'un des groupes carboxyl du tétrapyrrole : avec la condition que le reste tétrapyrrole ne représent pas un phéoph rble a.
- 5           2. Composition selon la revendication 1, dans laquelle l'acide aminé est un alpha amino acide.
- 10          3. Composition selon l'une des revendications 1 et 2, dans laquelle, le tétrapyrrole est une porphyrine, une chlorine ou une bactériochlorine.
- 15          4. Composition selon l'une quelconque des revendications 1 à 3, dans laquelle les substituants contenant un amide sont disposés de manière asymétrique sur la molécule de tétrapyrrole.
- 20          5. Composition selon la revendication 1, dans laquelle l'amide est :
- la disérynyl mésoporphyrine IX ;
  - la diglycyl mésoporphyrine IX ;
  - la di- $\alpha$ -(DL)-alanyl mésoporphyrine IX ;
  - la di- $\beta$ -alanyl mésoporphyrine IX ;
  - 25         - la di- $\epsilon$ -amino-n-caproyl mésoporphyrine IX ;
  - la diglycyl trans-mésochlorine IX ;
  - la diglycyl trans-mésochlorine e<sub>6</sub> ;
  - la diglycyl mésochlorine e<sub>4</sub> ;
  - la diglycyl hématoporphyrine IX ;
  - 30         - la diglycyl chlorine e<sub>6</sub> ;
  - la diglycyl protoporphyrine IX ;
  - la diglycyl deutéroporphyrine ;
  - la di- $\alpha$ -(DL)-alanyl trans-mésochlorine IX ;
  - la di- $\alpha$ -(DL)-alanyl mésochlorine e<sub>6</sub> ;
  - 35         - la di- $\alpha$ -(DL)-alanyl mésochlorine e<sub>4</sub> ;
  - la di- $\alpha$ -(DL)-alanyl hématoporphyrine IX ;
  - la di- $\alpha$ -(DL)-alanyl chlorine e<sub>6</sub> ;
  - la di- $\alpha$ -(DL)-alanyl protoporphyrine IX ;
  - la di- $\alpha$ -(DL)-alanyl deutéroporphyrine ;
  - 40         - la di- $\beta$ -(DL)-alanyl trans-mésochlorine IX ;
  - la di- $\beta$ -(DL)-alanyl mésochlorine e<sub>6</sub> ;
  - la di- $\beta$ -(DL)-alanyl mésochlorine e<sub>4</sub> ;
  - la di- $\beta$ -(DL)-alanyl hématoporphyrine IX ;
  - la di- $\beta$ -(DL)-alanyl chlorine e<sub>6</sub> ;
  - 45         - la di- $\beta$ -(DL)-alanyl protoporphyrine IX ;
  - la di- $\beta$ -(DL)-alanyl deutéroporphyrine ;
  - la di-L- $\alpha$ -sérinyl chlorine e<sub>6</sub> ;
  - la di-L- $\alpha$ -sérinyl trans-mésochlorine e<sub>6</sub> ;
  - la di-L- $\alpha$ -sérinyl trans-mésochlorine IX ;
  - 50         - la di-L- $\alpha$ -sérinyl trans-mésochlorine e<sub>4</sub> ;
  - la di-L- $\alpha$ -sérinyl hématoporphyrine IX ;
  - la di-L- $\alpha$ -sérinyl protoporphyrine IX ;
  - la di-L- $\alpha$ -sérinyl deutéroporphyrine ;
  - la di- $\epsilon$ -amino-n-caproyl-hématoporphyrine IX ;
  - 55         - la di- $\epsilon$ -amino-n-caproyl-chlorine e<sub>6</sub> ;
  - la di- $\epsilon$ -amino-n-caproyl-protoporphyrine IX ;
  - la di- $\epsilon$ -amino-n-caproyl-deutéroporphyrine ;
  - la mono-L-sérinyl mésochlorine e<sub>6</sub> ;
  - la mono-L-sérinyl deutérochlorine e<sub>6</sub> ;
  - la mono-L-sérinyl-2-formyl chlorine e<sub>6</sub> ;
  - la mono-L-sérinyl-2-acétyl chlorine e<sub>6</sub> ;
  - la mono-L-cystéinyl chlorine e<sub>6</sub> ;
  - la mono-L-asparaginyl chlorine e<sub>6</sub> ;

- la mono sérynyl chlorine e<sub>6</sub> ;
  - la mono-(DL) glycyl chlorin e<sub>6</sub> ;
  - l'alanyl chlorine e<sub>6</sub> ;
  - la mono-L-valyl chlorine e<sub>6</sub> ;
  - la mono-L-leucyl chlorine e<sub>6</sub> ;
  - la mono-L-isoleucyl chlorine e<sub>6</sub> ;
  - la mono-L-prolyl chlorine e<sub>6</sub> ;
  - la mono-L-méthionyl chlorine e<sub>6</sub> ;
  - la mono-L-thréoninyl chlorine e<sub>6</sub> ;
  - la tyrosyl chlorine e<sub>6</sub> ;
  - la glutaminyl chlorine e<sub>6</sub> ;
  - la lysyl chlorine e<sub>6</sub> ;
  - l'arginyl chlorine e<sub>6</sub> ;
  - l'histidyl chlorine e<sub>6</sub> ;
  - la  $\beta$ -alanyl chlorine e<sub>6</sub> ;
  - la mono- $\epsilon$ -amino-n-caproyl chlorine e<sub>6</sub> ;
  - la monoglycyl mésoporphyrine IX ;
  - la mono alanyl mésoporphyrine IX ;
  - la mono- $\beta$ -alanyl mésoporphyrine IX ;
  - la mono- $\epsilon$ -amino-n-caproyl mésoporphyrine IX ;
  - la mono- $\beta$ -alanyl-hématoporphyrine IX ;
  - la thréoninyl-2-formylichlorine e<sub>6</sub> ;
  - la mono-L-thréoninyl deuterochlorine e<sub>6</sub> ; ou
  - la mono-L-thréoninyl mésochlorine e<sub>6</sub>.
- 25            6. Utilisation d'un mono-, di- ou polyamide fluorescent d'un acide aminomonocarboxylique et d'un térapyrrole contenant un ou deux groupes carboxy de la structure telle que définie à l'une quelconque des revendications 1 à 5, ou d'un sel de celui-ci, et d'un support pharmaceutiquement acceptable pour celui-ci, pour la préparation d'une composition thérapeutique pour le photodiagnostic et/ou la photothérapie de tumeurs.
- 30

**Revendications pour l'Etat contractant suivant : AT**


- 35            1. Utilisation d'un mono-, di- ou polyamide fluorescent d'un acide aminomonocarboxylique et d'un composé de térapyrrole représenté par la formule :



40            45            50            55            ou d'un sel de celui-ci,  
ou des di- ou tétrahydrotétrapyrroles correspondants ; et d'un support pharmaceutiquement acceptable pour celui-ci ; où :

- R<sub>1</sub> représente méthyle,


5



ou

10

15



- R<sub>2</sub> représente H, vinyle, éthyle,


20



acétyle,

25

30




CH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>H, ou =CHCHO ;

- R<sub>3</sub> représente méthyle,


35

40



ou

45



50

- R<sub>4</sub> représente H, vinyle, éthyle,

55



CH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>H, =CHCHO, ou

$$\left\{ \begin{array}{l} -H \\ -\text{éthyle} \end{array} \right. ;$$

5

- R<sub>5</sub> représente méthyle ;
- R<sub>6</sub> représente H, CH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>H, CH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>R ou CO<sub>2</sub>H ;
- R<sub>7</sub> représente CH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>H, CH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>R, ou

10

$$\left\{ \begin{array}{l} -\text{CH}_2\text{CH}_2\text{CO}_2\text{H} \\ -H \end{array} \right. ;$$

15

- R<sub>8</sub> représente méthyle ou

20

$$\left\{ \begin{array}{l} -\text{CH}_3 \\ -H \end{array} \right. ;$$

25

- R<sub>9</sub> représente H, COOH, CH<sub>2</sub>COOH ou méthyle ;  
à la condition que, lorsque R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>7</sub> et R<sub>8</sub> représentent deux substituants ou sont bivalents et attachés au même carbone, le noyau pyrrole respectif auquel ils sont attachés est un dihydropyrrole ;
  - R représente alkyle inférieur ou benzyle ;  
avec la condition qu'au moins l'un parmi R<sub>1</sub>-R<sub>9</sub> comprenne un groupe carboxyle libre, et que d s liaisons amide (1 à 4) soient formées entre le groupe amino de l'acide aminomonocarboxylique et l'un des groupes carboxyle du tétrapyrrole : avec la condition que le reste tétrapyrrole ne représente pas un phéophorblide a.
- pour la préparation d'une composition thérapeutique pour le photodiagnostic et/ou la photothérapie d tumeurs.

30

2. Utilisation selon la revendication 1, caractérisée par le fait que l'acide aminé est un alpha amino acide.

40

45

50

55